A C177536 GDC Property Terminology C159229 Cytogenetic Risk Group-CALGB Criteria for AML A classification strategy for Acute Myeloid Leukemia (AML)developed by the cancer research cooperative group Cancer And Leukemia Group B that assigns a rating based on the cytogenetic and molecular features of a particular disease. calgb_risk_group calgb risk group A C177536 GDC Property Terminology C164683 Adverse Event Treatment Emergent Indicator treatment_emergent_adverse_event treatment emergent adverse event A C177536 GDC Property Terminology C206453 Genome Doubling Event Number The number of genome doubling events observed. genome_doubling genome doubling A C177536 GDC Property Terminology C206454 Cancer DNA to Total Tumor Tissue DNA Ratio Measurement The determination of the ratio of cancer-derived DNA compared to total DNA in a tumor sample. The measurement may be expressed as a ratio, fraction or percentage. cancer_dna_fraction cancer dna fraction A C177536 GDC Property Terminology C206455 Subclonal Genome to Total Tumor Tissue Genome Ratio Measurement The determination of the ratio of subclonal genomic sequences compared to the total genomic sequences in a tumor sample. The measurement may be expressed as a ratio, fraction or percentage. subclonal_genome_fraction subclonal genome fraction A C177536 GDC Property Terminology C206456 Curated Model Identifier The index number associated with a curated model. curated_model_index curated model index A C177536 GDC Property Terminology C206478 Prescribed Dose Units The unit of measure that is associated with the dose of the prescribed agent. prescribed_dose_units prescribed dose units A C177536 GDC Property Terminology C206479 Hormone Replacement Therapy Status Indicator An indication as to whether a subject has ever received hormone replacement therapy. hormonal_replacement_therapy_status hormonal replacement therapy status A C177536 GDC Property Terminology C206480 Papillary Renal Cell Carcinoma Type Indicator An indication as to whether a subject has been diagnosed with type 1 or type 2 papillary renal cell carcinoma. prcc_type prcc type C C177536 GDC Property Terminology C106551 Number of Pregnancies A measurement of the total number of pregnancy events experienced by the female subject. number_of_pregnancies number of pregnancies C C177536 GDC Property Terminology C125738 FIGO Stage A set of staging terms for gynecologic cancers developed by the International Federation of Gynecology and Obstetrics (FIGO). figo_stage figo stage C C177536 GDC Property Terminology C129439 Medulloblastoma Molecular Subtypes A term that refers to the classification of medulloblastomas based on their molecular characteristics. medulloblastoma_molecular_classification medulloblastoma molecular classification C C177536 GDC Property Terminology C171435 Specimen Anatomic Site The anatomic site from which a biospecimen was obtained. biospecimen_anatomic_site biospecimen anatomic site C C177536 GDC Property Terminology C177609 Hepatitis Serology A set of tests that is used to determine if a subject has been or is currently infected with a Hepatitis virus, is shedding Hepatitis virus or has immunity to Hepatitis viruses. viral_hepatitis_serology_tests viral hepatitis serology tests C C177536 GDC Property Terminology C198198 Therapeutic Agent Level Achieved Indicator An indication that the intended level of therapeutic agent was achieved in an individual. therapeutic_levels_achieved therapeutic level achieved || therapeutic levels achieved || therapeutic_level_achieved A C177537 GDC Value Terminology C111124 Abnormal Cell Count The determination of the amount of abnormal cells present in a sample. Abnormal Cells | laboratory_test C25294 laboratory_test A C177537 GDC Value Terminology C113505 t(9;11) A translocation between chromosome 9 and chromosome 11. t(9;11) | chromosomal_translocation C3420 chromosomal_translocation A C177537 GDC Value Terminology C114095 Full Term Birth Birth at 39 weeks and 0 days through 40 weeks and 6 days. Full Term Birth, NOS | pregnancy_outcome C90491 pregnancy_outcome A C177537 GDC Value Terminology C117116 t(9;22) A translocation between chromosome 9 and chromosome 22 that may be associated with Philadelphia chromosome and increased susceptibility to several types of leukemia. t(9;22) | chromosomal_translocation C3420 chromosomal_translocation A C177537 GDC Value Terminology C123276 BK Virus Infection An infection caused by the BK virus. It usually causes an asymptomatic infection, except in immunocompromised individuals where it may cause nephropathy or hemorrhagic cystitis. BK Virus | risk_factors C17103 risk_factors A C177537 GDC Value Terminology C128652 t(4;11) A cytogenetic abnormality that involves a translocation between chromosomes 4 and 11. t(4;11) | chromosomal_translocation C3420 chromosomal_translocation A C177537 GDC Value Terminology C128656 t(15;17) A cytogenetic abnormality that involves a translocation between chromosomes 15 and 17. t(15;17) | chromosomal_translocation C3420 chromosomal_translocation A C177537 GDC Value Terminology C12999 Major Salivary Gland One of the three larger salivary glands including the parotid, submandibular and sublingual glands. Major salivary gland, NOS | progression_or_recurrence_anatomic_site || Major salivary gland, NOS | site_of_resection_or_biopsy || Major salivary gland, NOS | tissue_or_organ_of_origin C156421 || C156422 || C177570 site_of_resection_or_biopsy || tissue_or_organ_of_origin || progression_or_recurrence_anatomic_site A C177537 GDC Value Terminology C153194 Transcriptome The complete set of RNA transcripts that are produced by the genome, under specific circumstances or in a specific cell. Transcriptome Profiling | data_category C175886 data_category A C177537 GDC Value Terminology C158623 Greater Than or Equal to Four 4+ | number_of_pregnancies C106551 number_of_pregnancies A C177537 GDC Value Terminology C160757 Favorable CALGB Criteria A rating for AML by CALGB which indicates the outlook on the patient recovery is favored towards recovery. Favorable | calgb_risk_group C159229 calgb_risk_group A C177537 GDC Value Terminology C160758 Intermediate CALGB Criteria A rating for AML by CALGB which indicates the outlook on the patient recovery can be considered between favorable and poor. Intermediate/Normal | calgb_risk_group C159229 calgb_risk_group A C177537 GDC Value Terminology C160759 Poor CALGB Criteria A rating for AML by CALGB which indicates the outlook on the patient recovery can be considered poor. Poor | calgb_risk_group C159229 calgb_risk_group A C177537 GDC Value Terminology C169928 Efaprinermin Alfa A Fc-engineered human fusion protein composed of two trimers of tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18; GlTRL) linked to an immunoglobulin Fc domain (GITRL-Fc), with potential immunostimulatory and antineoplastic activities. Upon administration, efaprinermin alfa targets, binds to and activates its co-stimulatory surface receptor (glucocorticoid-induced tumor necrosis factor receptor (GITR; TNFRSF18) expressed on T-lymphocytes and certain tumor cell types. This activates T-lymphocytes, causes T-lymphocyte proliferation and suppresses the activity of regulatory T-cells (Treg). This promotes cytotoxic T-lymphocyte (CTL)-mediated killing of tumor cells. GITRL, a member of the tumor necrosis factor (TNF) family of ligands, functions to activate the co-stimulatory receptor GITR to enhance T-cell modulated immune responses. Trimeric GITRL-Fc OMP-336B11 | therapeutic_agents C1909 therapeutic_agents A C177537 GDC Value Terminology C173385 Cutaneous Merkel Cell Carcinoma A rare aggressive neuroendocrine carcinoma that arises from the skin and most often affects older individuals. It is usually located in the head, neck, and extremities. The tumor is composed of small round cells with scanty cytoplasm. Merkel cell polyomavirus is implicated in the majority of cases. Primary cutaneous neuroendocrine carcinoma | primary_diagnosis C177621 primary_diagnosis A C177537 GDC Value Terminology C175740 Alnuctamab A bispecific T-cell engager (BiTE) antibody directed against both the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, alnuctamab binds bivalently to BCMA expressed on tumor cells and monovalently to CD3 expressed on cytotoxic T-lymphocytes (CTLs). This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. BCMA x CD3 T-cell Engaging Antibody CC-93269 | therapeutic_agents C1909 therapeutic_agents A C177537 GDC Value Terminology C17646 Bone Scan A nuclear imaging method used to evaluate pathological bone metabolism. Bone Scan, NOS | imaging_type C17369 imaging_type A C177537 GDC Value Terminology C181250 Immunophenotyping Assay A type of immunoassay that examines the markers or antigens associated with the cell surface, nucleus, or cytoplasm. Immunophenotyping, NOS | molecular_analysis_method C19770 molecular_analysis_method A C177537 GDC Value Terminology C184921 Lerapolturev A recombinant, live attenuated, nonpathogenic oncolytic virus containing the oral poliovirus Sabin type 1 in which the internal ribosomal entry site (IRES) is replaced with the IRES from human rhinovirus type 2 (HRV2), with potential antineoplastic activity. Upon administration of lerapolturev, the poliovirus is selectively taken up by and replicates in tumor cells expressing CD155 (poliovirus receptor, PVR or NECL5) eventually causing tumor cell lysis. Following the lysis of infected cells, the replicated virus is released and can infect adjacent cells, which both induces further tumor cell oncolysis and may activate, through the release of tumor-associated antigens (TAAs) and inflammatory mediators from the lysed tumor cells, the immune system to mount an anti-tumor immune response. This further kills tumor cells. This may also stimulate long-term anti-tumor immunity. Additionally, lerapolturev can induce a systemic anti-tumor immune response through engagement with antigen-presenting cells (APCs) upon CD155 binding thereby further killing tumor cells. CD155, an oncofetal cell adhesion molecule and tumor antigen, is ectopically expressed in certain cancers, such as glioblastoma multiforme (GMB), and plays an important role in tumor cell migration, invasion, and metastasis. Due to the heterologous HRV2 IRES in this recombinant virus, lerapolturev only propagates in susceptible CD155-expressing, nonneuronal neoplastic cells. Recombinant Oncolytic Poliovirus PVS-RIPO | therapeutic_agents C1909 therapeutic_agents A C177537 GDC Value Terminology C188300 FIGO Stage IIC A FIGO stage term that applies to gynecologic cancers. For endometrial cancer, it refers to cancer of aggressive histological type with any myometrial invasion. Stage IIC | figo_stage C125738 figo_stage A C177537 GDC Value Terminology C188608 Rhenium Re 186 Obisbemeda A therapeutic preparation consisting of the beta-emitting radioisotope rhenium Re 186 encapsulated in a nanoliposome, with potential antineoplastic activity. Upon intratumoral infusion of liposomal rhenium Re 186, the radioisotope releases radiation, which directly kills the tumor cells. The nanoliposomes facilitate the retention of the radioisotope by the tumor cells and localize the radiocytotoxicity to the tumor while sparing surrounding normal, healthy cells. Re-186 has a short half-life and a short path length, which contributes further to limiting the radiotoxicity to the tumor cells. Liposomal Rhenium Re 186 | therapeutic_agents C1909 therapeutic_agents A C177537 GDC Value Terminology C203075 Lacutoclax An orally bioavailable inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, lacutoclax targets, binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Bcl-2 Inhibitor LP-108 | therapeutic_agents C1909 therapeutic_agents A C177537 GDC Value Terminology C203250 Neuroendocrine Tumor G1 A well-differentiated, low-grade epithelial neoplasm with neuroendocrine differentiation. It arises from multiple sites, including the digestive system, lung, and head and neck. G1 | who_nte_grade C177567 who_nte_grade A C177537 GDC Value Terminology C203251 Neuroendocrine Tumor G3 A well-differentiated, high-grade epithelial neoplasm with neuroendocrine differentiation. It usually arises from the digestive system. G3 | who_nte_grade C177567 who_nte_grade A C177537 GDC Value Terminology C204352 Genomic Variant Call Format A text file format used for storing gene sequence variations. It is a type of variant call format that has a record for all sites, whether there is a variant call there or not. The format includes metrics of the confidence that positions are actually non-variant vs. a factor of minimum read-depth and genotype quality. gVCF | data_format C42761 data_format A C177537 GDC Value Terminology C204843 Low-CSD Melanoma, Superficial Spreading Melanoma Subtype A cutaneous melanoma that develops on sun exposed sites with low cumulative sun damage (CSD). It is characterized by a prominent junctional and intraepidermal component with intraepidermal proliferation of individual atypical melanocytes and formation of nests of atypical melanocytes along the dermal-epidermal junction. The dermal component is composed of atypical melanocytes that fail to mature. The atypical melanocytes have large nuclei, prominent nucleoli, and eosinophilic or lightly pigmented cytoplasm. It is the most common melanoma subtype in the Western world. 8743/3 | morphology || Superficial spreading melanoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C205125 Nodular Melanoma A melanoma that arises from the skin and mucosal sites. It is characterized by a vertical growth phase and lacks a significant radial growth phase. It may or may not arise from a pre-existing nevus. Morphologically, it is characterized by the presence of cohesive aggregates of neoplastic melanocytes in the dermis that often exhibit an epithelioid appearance. The overlying epidermis is often involved. 8721/3 | morphology || Nodular melanoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C205459 Apocrine Cystadenoma A rare, benign cystic neoplasm that arises from the apocrine gland. It is characterized by the presence of papillary-like epithelial projections and more complex architectural patterns compared to apocrine hidrocystoma. 8401/0 | morphology || Apocrine cystadenoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C205462 Eccrine Poroma A poroma with eccrine differentiation. Eccrine poroma | primary_diagnosis C177621 primary_diagnosis A C177537 GDC Value Terminology C206079 Trichodiscoma A rare hamartomatous papular lesion that arises from the hair follicle. It shares morphological features with fibrofolliculoma, but in contrast to fibrofolliculoma, the predominant component is stroma. 8391/0 | morphology || Trichodiscoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C206457 Somatic Mutation Index File An electronic data file containing the index for somatic mutation calls. Somatic Mutation Index | data_type C172272 data_type A C177537 GDC Value Terminology C206459 Germline Mutation Index File An electronic data file containing the index for germline mutation calls. Germline Mutation Index | data_type C172272 data_type A C177537 GDC Value Terminology C206460 Copy Number Variation Model File An electronic data file containing inferred models for determining genomic copy number alterations in molecular data sets. CNV Model | data_type C172272 data_type A C177537 GDC Value Terminology C206461 Localized Extraprostatic Extension A finding indicating the presence of a prostatic carcinoma that has invaded the prostatic capsule and has spread to nearby tissues. Extraprostatic Extension, Localized | imaging_findings C199145 imaging_findings A C177537 GDC Value Terminology C206462 Extraprostatic Extension with Regional Lymphadenopathy A finding indicating the presence of a prostatic carcinoma that has invaded the prostatic capsule and has spread to regional lymph nodes, resulting in enlargement of the affected lymph nodes. Extraprostatic Extension, Regional Lymphadenopathy | imaging_findings C199145 imaging_findings A C177537 GDC Value Terminology C206463 Extraprostatic Extension Absent An indication that there was no evidence for prostatic capsule invasion or spread in a patient with prostate carcinoma. No Evidence of Extraprostatic Extension | imaging_findings C199145 imaging_findings A C177537 GDC Value Terminology C206464 Prior to Adjuvant Therapy Occurring before the administration of adjuvant therapy. Prior to Adjuvant Therapy | timepoint_category C198201 timepoint_category A C177537 GDC Value Terminology C206465 Within 2 Months After Completion of First-Course Treatment Occurring within the 2 months that follow the completion of a first course of treatment. Within 2 Months After Completion of First-Course Treatment | timepoint_category C198201 timepoint_category A C177537 GDC Value Terminology C206467 GeneChip Human Genome U133 Plus 2.0 Array A proprietary, next-generation transcriptome profiling, microarray chip developed by Affymetrix that can be leveraged to analyze the expression level of over 47,000 human transcripts, including those in the U133A array. GeneChip U133 Plus 2.0 | platform C45378 platform A C177537 GDC Value Terminology C206468 GeneChip Human Genome U133A Array A proprietary, next-generation transcriptome profiling, microarray chip developed by Affymetrix that can be leveraged to analyze the expression level of 18,400 human transcripts and variants. GeneChip U133A | platform C45378 platform A C177537 GDC Value Terminology C206481 Aligned Read Coverage 10-25x The range of coverage for aligned reads was between 10x and 25x. 10x-25x | wgs_coverage C200470 wgs_coverage A C177537 GDC Value Terminology C206482 Aligned Read Coverage Greater than or Equal to 150x The range of coverage for aligned reads was greater than or equal to 150x. 150x+ | wgs_coverage C200470 wgs_coverage A C177537 GDC Value Terminology C206483 Aligned Read Coverage 16x The extent of coverage for aligned reads was 16x. 16 | wgs_coverage C200470 wgs_coverage A C177537 GDC Value Terminology C206484 Aligned Read Coverage 25-150x The range of coverage for aligned reads was between 25x and 150x. 25x-150x | wgs_coverage C200470 wgs_coverage A C177537 GDC Value Terminology C25784 RAS Family Gene A family of genes that encode structurally similar small GTPases involved in a variety of signal transduction pathways. Mutation of genes in this family is associated with cancer. RAS, NOS | gene_symbol || RAS, NOS | second_gene_symbol C171253 || C173595 second_gene_symbol || gene_symbol A C177537 GDC Value Terminology C27527 Tubular Apocrine Adenoma A benign dermal adnexal neoplasm with apocrine differentiation. It usually occurs in the scalp and has a female predilection. It presents as an asymptomatic solitary nodule. It is characterized by a lobular architecture. The lobules are composed by tubular structures lined by epithelial cells. There is no cytologic atypia or mitotic figures present. 8408/0 | morphology || Eccrine papillary adenoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C27886 Type 1 Papillary Renal Cell Carcinoma A papillary renal cell carcinoma characterized by the presence of papillae covered by small cells with scant amount of cytoplasm. The cells are arranged in a single layer on the basement membrane of the papillae. Type 1 | prcc_type C206480 prcc_type A C177537 GDC Value Terminology C27887 Type 2 Papillary Renal Cell Carcinoma A papillary renal cell carcinoma characterized by the presence of papillae covered by cells of a higher nuclear grade as compared to type 1 papillary renal cell carcinoma. The cells have eosinophilic cytoplasm and pseudostratified nuclei. Type 2 | prcc_type C206480 prcc_type A C177537 GDC Value Terminology C32488 Dura Mater The outermost, toughest, and most fibrous of the three membranes (meninges) that surround and protect the brain and spinal cord. Dura Mater | sites_of_involvement C173263 sites_of_involvement A C177537 GDC Value Terminology C35479 Retinal Arteriovenous Malformation A vascular malformation of the retina that consists of arteriovenous communications and shunts. It occurs as an isolated lesion or as a component of the Wyburn-Mason syndrome. 9123/0 | morphology || Racemose hemangioma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C40412 Ineligibility The state or quality of being disqualified by law, rule, or provision. Patient Ineligible | reason_treatment_not_given C102704 reason_treatment_not_given A C177537 GDC Value Terminology C42535 Second A unit of time, one of the seven base units of the International System of Units (Systeme International d'Unites, SI). The second is the duration of 919 263 177 0 periods of the specified light radiation corresponding to the transition between the two hyperfine levels of the caesium 133 atom in its ground state at 0 K. According to the convention, 60 seconds constitute one minute; 3,600 seconds constitute one hour. Seconds | test_units C67415 test_units A C177537 GDC Value Terminology C4488 Angiokeratoma A vascular lesion in the papillary dermis that results from ectasia of pre-existing vessels. It is associated with secondary proliferative changes in the overlying epidermis. It can present with widespread lesions or as a localized lesion. 9141/0 | morphology || Angiokeratoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis A C177537 GDC Value Terminology C48579 International Unit The unitage assigned by the WHO to International Biological Standards - substances, classed as biological according to the criteria provided by WHO Expert Committee on Biological Standardization (e.g. hormones, enzymes, and vaccines), to enable the results of biological and immunological assay procedures to be expressed in the same way throughout the world. The definition of an international unit is generally arbitrary and technical, and has to be officially approved by the International Conference for Unification of Formulae. IU | test_units C67415 test_units A C177537 GDC Value Terminology C4922 Diverticulosis A finding indicating the presence of multiple pouches, usually in the colonic or gastric wall. Diverticulosis | risk_factors C17103 risk_factors A C177537 GDC Value Terminology C53256 Adverse Event Unrelated to Intervention A characteristic used to qualify the adverse event as clearly not related to the medical intervention. Unrelated | treatment_emergent_adverse_event C164683 treatment_emergent_adverse_event A C177537 GDC Value Terminology C53257 Adverse Event Unlikely Related to Intervention A characteristic used to qualify the adverse event as unlikely related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a temporal relationship to the medical intervention which makes a causal relationship improbable, and in which other interventions or underlying disease provide plausible explanations. Unlikely | treatment_emergent_adverse_event C164683 treatment_emergent_adverse_event A C177537 GDC Value Terminology C53258 Adverse Event Possibly Related to Intervention A characteristic indicating that an adverse event may be related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a reasonable time sequence to administration of the drug, but which could also be explained by concurrent disease or other drugs or chemicals. Information on drug withdrawal may be lacking or unclear. Possibly | treatment_emergent_adverse_event C164683 treatment_emergent_adverse_event A C177537 GDC Value Terminology C53259 Adverse Event Probably Related to Intervention A characteristic used to qualify the adverse event as likely related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, with a reasonable time sequence to the medical intervention, unlikely to be attributed to concurrent disease or other medical interventions, and which follows a clinically reasonable response on withdrawal (dechallenge). Rechallenge information is not required to fulfill this definition. Probably | treatment_emergent_adverse_event C164683 treatment_emergent_adverse_event A C177537 GDC Value Terminology C53260 Adverse Event Definitely Related to Intervention A characteristic used to qualify the adverse event as certainly related to the medical intervention. According to WHO causality assessment criteria of suspected adverse reactions it is applicable to a clinical event, including laboratory test abnormality, occurring in a plausible time relationship to medical intervention, and which cannot be explained by concurrent disease or other interventions. The response to withdrawal of the medical product (dechallenge) should be clinically plausible. The event must be definitive pharmacologically or phenomenologically, using a satisfactory rechallenge procedure if necessary. Definitely | treatment_emergent_adverse_event C164683 treatment_emergent_adverse_event A C177537 GDC Value Terminology C54986 Cardiac Ischemia or Infarction, CTCAE Cardiac Ischemia | adverse_event C41331 adverse_event A C177537 GDC Value Terminology C55159 Glomerular Filtration Rate, CTCAE Glomerular Filtration Rate Decreased | adverse_event C41331 adverse_event A C177537 GDC Value Terminology C56095 Joint Pain, CTCAE Joint Pain | adverse_event C41331 adverse_event A C177537 GDC Value Terminology C57074 Renal Failure, CTCAE Renal Failure | adverse_event C41331 adverse_event A C177537 GDC Value Terminology C57086 Ureter Obstruction, CTCAE Ureteral Obstruction | adverse_event C41331 adverse_event A C177537 GDC Value Terminology C58010 Rash Desquamation, CTCAE Rash/Desquamation | adverse_event C41331 adverse_event A C177537 GDC Value Terminology C62710 Immunoglobulin Therapy The use of immunoglobulins in the treatment of any disease or disorder. Immunoglobulin | immunosuppressive_treatment_type C574 immunosuppressive_treatment_type A C177537 GDC Value Terminology C66832 One The smallest natural number and quantity it denotes: a single entity, unit, or object. 1 | number_of_pregnancies || 1 | weiss_assessment_score C104014 || C106551 weiss_assessment_score || number_of_pregnancies A C177537 GDC Value Terminology C66833 Two A natural number greater than 1 and less than 3 and the quantity that it denotes: the sum of one and one. 2 | number_of_pregnancies || 2 | weiss_assessment_score C104014 || C106551 weiss_assessment_score || number_of_pregnancies A C177537 GDC Value Terminology C66834 Three A natural number greater than 2 and less than 4 and the quantity that it denotes: the sum of two and one. 3 | number_of_pregnancies || 3 | weiss_assessment_score C104014 || C106551 weiss_assessment_score || number_of_pregnancies A C177537 GDC Value Terminology C66835 Four A natural number greater than 3 and less than 5 and the quantity that it denotes: the sum of three and one. 4 | weiss_assessment_score C104014 weiss_assessment_score A C177537 GDC Value Terminology C66836 Five A natural number greater than 4 and less than 6 and the quantity that it denotes: the sum of four and one. 5 | weiss_assessment_score C104014 weiss_assessment_score A C177537 GDC Value Terminology C66837 Six A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one. 6 | weiss_assessment_score C104014 weiss_assessment_score A C177537 GDC Value Terminology C66838 Seven A natural number greater than 6 and less than 8 and the quantity that it denotes: the sum of six and one. 7 | weiss_assessment_score C104014 weiss_assessment_score A C177537 GDC Value Terminology C66839 Eight A natural number greater than 7 and less than 9 and the quantity that it denotes: the sum of seven and one. 8 | weiss_assessment_score C104014 weiss_assessment_score A C177537 GDC Value Terminology C66840 Nine A natural number greater than 8 and less than 10 and the quantity that it denotes: the sum of nine and one. 9 | weiss_assessment_score C104014 weiss_assessment_score A C177537 GDC Value Terminology C67251 Million Cells per Microliter A unit of cell concentration expressed as a number of cells in millions per unit volume equal to one microliter. x10^6 cells/mcL | test_units C67415 test_units A C177537 GDC Value Terminology C67432 Nanomole per Liter A unit of concentration (molarity unit) equal to one billionth of a mole (10E-9 mole) of solute in one liter of solution. nmol/L | test_units C67415 test_units A C177537 GDC Value Terminology C91742 MPO Gene This gene is involved in the modulation of neutrophil microbicidal activity. MPO | gene_symbol || MPO | second_gene_symbol C171253 || C173595 second_gene_symbol || gene_symbol A C177537 GDC Value Terminology C93207 DNA Gene-expression Microarray Expression Array | experimental_strategy C43622 experimental_strategy A C177537 GDC Value Terminology C94575 Scarlet Fever A streptococcal infection, mainly occurring among children, that is characterized by a red skin rash, sore throat, and fever. Scarlet Fever | risk_factors C17103 risk_factors C C177537 GDC Value Terminology C102330 Perihilar Lymph Node A lymph node located in the area around the hilum of an organ. Hilar | lymph_node_involved_site || Lymph Node(s) Hilar | biospecimen_anatomic_site || Lymph Node(s) Hilar | treatment_anatomic_sites || Lymph Node, Hilar | sites_of_involvement C171435 || C173263 || C33027 || C70729 biospecimen_anatomic_site || sites_of_involvement || lymph_node_involved_site || treatment_anatomic_sites C C177537 GDC Value Terminology C103384 Common Iliac Lymph Node A lymph node located adjacent to the common iliac artery. (NCI) Iliac-common | lymph_node_involved_site || Lymph Node(s) Iliac-Common | biospecimen_anatomic_site || Lymph Node(s) Iliac-Common | treatment_anatomic_sites || Lymph Node, Iliac-Common | sites_of_involvement C171435 || C173263 || C33027 || C70729 biospecimen_anatomic_site || sites_of_involvement || lymph_node_involved_site || treatment_anatomic_sites C C177537 GDC Value Terminology C103404 Hepatitis B DNA Measurement The determination of the amount of hepatitis B virus DNA in a sample. HBV DNA | viral_hepatitis_serology_tests C177609 viral_hepatitis_serology_tests C C177537 GDC Value Terminology C107503 Nogapendekin Alfa A mutated form of the cytokine interleukin (IL)-15 (IL-15N72D), with potential immunomodulating and antineoplastic activities. Upon administration, nogapendekin alfa binds to the IL-15 receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory T-cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. Nogapendekin Alfa | therapeutic_agents || Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C112004 Rupitasertib An orally available inhibitor of the serine/threonine protein kinases ribosomal protein S6 Kinase (p70S6K) and Akt (protein kinase B), with potential antineoplastic activity. Upon administration, rupitasertib binds to and inhibits the activity of p70S6K and Akt. This prevents the activation of the PI3K/Akt/p70S6K signaling pathway and inhibits tumor cell proliferation in cancer cells that have an overactivated PI3K/Akt/p70S6K signaling pathway. Constitutive activation and dysregulated signaling of the PI3K/Akt/p70S6K pathway are frequently associated with tumorigenesis of many tumor types; targeting multiple kinases in this pathway is more efficacious than targeting a single kinase. p70S6K/Akt Inhibitor MSC2363318A | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C113730 Grade X A morphologic qualifier indicating that the grade of a neoplasm cannot be assessed. GX | tumor_grade || GX | who_nte_grade C177567 || C28076 who_nte_grade || tumor_grade C C177537 GDC Value Terminology C117108 HBV Genotype Assay An assay used to determine which hepatitis B virus genome(s) is present in an infection. Seven genotypes of HBV (designated A through G) have been identified. Different genotypes are prevalent in different geographical areas and each carries a different risk of development of hepatocellular carcinoma. HBV Genotype | viral_hepatitis_serology_tests C177609 viral_hepatitis_serology_tests C C177537 GDC Value Terminology C117109 HCV Genotype Assay An assay for determining the genotype(s) of hepatitis C virus (HCV) in plasma or serum from HCV-infected individuals. Six major genotypes are recognized and they vary in their response to treatment. HCV Genotype | viral_hepatitis_serology_tests C177609 viral_hepatitis_serology_tests C C177537 GDC Value Terminology C117290 Ibrilatazar An orally bioavailable, lipid analogue and inhibitor of raptor-mammalian target of rapamycin (mTOR) (mTOR complex 1; mTORC1), rictor-mTOR (mTOR complex 2; mTORC2) and dihydrofolate reductase (DHFR) with potential antineoplastic activity. Upon oral administration, ibrilatazar binds to and inhibits both mTORC1 and mTORC2, which may result in apoptosis and a decrease in proliferation in mTORC1/2-expressing tumor cells. mTOR is a serine/threonine kinase that is upregulated in some tumors; it plays an important role in the PI3K/Akt/mTOR signaling pathway which is often deregulated in cancer cells. In addition, ibrilatazar inhibits DHFR, an enzyme that reduces dihydrofolic acid to tetrahydrofolic acid, thereby blocking tetrahydrofolate synthesis, and resulting in both the depletion of nucleotide precursors and the inhibition of DNA, RNA and protein synthesis. This induces autophagy-induced cell death and further inhibition of cell proliferation. mTORC1/mTORC2/DHFR Inhibitor ABTL0812 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C12253 Upper Third of the Esophagus The upper one third of esophagus in which the muscle layer is composed of muscle cells of the striated type. Esophageal; Proximal | biospecimen_anatomic_site || Esophagus, Upper Third | sites_of_involvement || Upper third of esophagus | progression_or_recurrence_anatomic_site || Upper third of esophagus | site_of_resection_or_biopsy || Upper third of esophagus | tissue_or_organ_of_origin C156421 || C156422 || C171435 || C173263 || C177570 site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site C C177537 GDC Value Terminology C12254 Middle Third of the Esophagus The middle one third of the esophagus in which the muscle layer is composed of muscle cells of the striated and smooth types. Esophageal; Mid | biospecimen_anatomic_site || Esophagus, Middle Third | sites_of_involvement || Middle third of esophagus | progression_or_recurrence_anatomic_site || Middle third of esophagus | site_of_resection_or_biopsy || Middle third of esophagus | tissue_or_organ_of_origin C156421 || C156422 || C171435 || C173263 || C177570 site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site C C177537 GDC Value Terminology C12255 Lower Third of the Esophagus The lower one third of the esophagus in which the muscle layer is composed of muscle cells predominantly of the smooth type. Esophageal; Distal | biospecimen_anatomic_site || Esophagus, Lower Third | sites_of_involvement || Lower third of esophagus | progression_or_recurrence_anatomic_site || Lower third of esophagus | site_of_resection_or_biopsy || Lower third of esophagus | tissue_or_organ_of_origin C156421 || C156422 || C171435 || C173263 || C177570 site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site C C177537 GDC Value Terminology C12269 Head of the Pancreas That portion of the pancreas lying in the concavity of the duodenum. Head of pancreas | progression_or_recurrence_anatomic_site || Head of pancreas | site_of_resection_or_biopsy || Head of pancreas | tissue_or_organ_of_origin || Pancreas Head | sites_of_involvement C156421 || C156422 || C173263 || C177570 site_of_resection_or_biopsy || tissue_or_organ_of_origin || sites_of_involvement || progression_or_recurrence_anatomic_site C C177537 GDC Value Terminology C12270 Body of the Pancreas The part of the pancreas from the point where it crosses the portal vein to the point where it enters the lienorenal ligament. Body of pancreas | progression_or_recurrence_anatomic_site || Body of pancreas | site_of_resection_or_biopsy || Body of pancreas | tissue_or_organ_of_origin || Pancreas Body | sites_of_involvement C156421 || C156422 || C173263 || C177570 site_of_resection_or_biopsy || tissue_or_organ_of_origin || sites_of_involvement || progression_or_recurrence_anatomic_site C C177537 GDC Value Terminology C12271 Tail of the Pancreas The left extremity of the pancreas within the lienorenal ligament. Pancreas Tail | sites_of_involvement || Tail of pancreas | progression_or_recurrence_anatomic_site || Tail of pancreas | site_of_resection_or_biopsy || Tail of pancreas | tissue_or_organ_of_origin C156421 || C156422 || C173263 || C177570 site_of_resection_or_biopsy || tissue_or_organ_of_origin || sites_of_involvement || progression_or_recurrence_anatomic_site C C177537 GDC Value Terminology C12272 Pancreatic Duct A duct joining the pancreas to the common bile duct to supply pancreatic juices. Pancreas Duct | sites_of_involvement || Pancreatic duct | progression_or_recurrence_anatomic_site || Pancreatic duct | site_of_resection_or_biopsy || Pancreatic duct | tissue_or_organ_of_origin C156421 || C156422 || C173263 || C177570 site_of_resection_or_biopsy || tissue_or_organ_of_origin || sites_of_involvement || progression_or_recurrence_anatomic_site C C177537 GDC Value Terminology C12320 Parametrium The subserous connective tissue of the pelvic floor of the supracervical portion of the uterus. The parametrium extends laterally between the layers of the broad ligament. Parametrium | progression_or_recurrence_anatomic_site || Parametrium | site_of_resection_or_biopsy || Parametrium | tissue_or_organ_of_origin || Parametrium | treatment_anatomic_sites || Parametrium, Left | sites_of_involvement || Parametrium, NOS | sites_of_involvement || Parametrium, Right | sites_of_involvement C156421 || C156422 || C173263 || C177570 || C70729 site_of_resection_or_biopsy || tissue_or_organ_of_origin || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_sites C C177537 GDC Value Terminology C12389 Esophagus The portion of the digestive canal between the pharynx and stomach. It is about 25 cm long and consists of three parts: the cervical part, from the cricoid cartilage to the thoracic inlet; thoracic part, from thoracic inlet to the diaphragm; and abdominal part, below the diaphragm to the cardiac opening of the stomach. Esophagus | biospecimen_anatomic_site || Esophagus | primary_site || Esophagus | treatment_anatomic_sites || Esophagus, NOS | progression_or_recurrence_anatomic_site || Esophagus, NOS | site_of_resection_or_biopsy || Esophagus, NOS | sites_of_involvement || Esophagus, NOS | tissue_or_organ_of_origin C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C70729 site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || treatment_anatomic_sites C C177537 GDC Value Terminology C12393 Pancreas An organ behind the lower part of the stomach that is the shape of a fish and about the size of a hand. It is a compound gland composed of both exocrine and endocrine tissues. The endocrine pancreas makes insulin so that the body can use glucose (sugar) for energy. The exocrine pancreas makes enzymes that help the body digest food. Spread all over the pancreas are areas called the Islets of Langerhans. The cells in these areas each have a special purpose. The alpha cells make glucagon, which raises the level of glucose in the blood; the beta cells make insulin; the delta cells make somatostatin. There are also PP cells and D1 cells, about which little is known. Pancreas | biospecimen_anatomic_site || Pancreas | max_tumor_bulk_site || Pancreas | primary_site || Pancreas | treatment_anatomic_sites || Pancreas, NOS | progression_or_recurrence_anatomic_site || Pancreas, NOS | site_of_resection_or_biopsy || Pancreas, NOS | sites_of_involvement || Pancreas, NOS | tissue_or_organ_of_origin C156421 || C156422 || C158874 || C171435 || C173263 || C177570 || C188396 || C70729 site_of_resection_or_biopsy || tissue_or_organ_of_origin || primary_site || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || max_tumor_bulk_site || treatment_anatomic_sites C C177537 GDC Value Terminology C12426 Salivary Gland An exocrine gland that secretes saliva. Salivary glands are mostly located in and around the oral cavity. Salivary Gland | biospecimen_anatomic_site || Salivary Gland | treatment_anatomic_sites || Salivary gland | sites_of_involvement C171435 || C173263 || C70729 biospecimen_anatomic_site || sites_of_involvement || treatment_anatomic_sites C C177537 GDC Value Terminology C12469 Pleura The tissue that lines the wall of the thoracic cavity and the surface of the lungs. Pleura | biospecimen_anatomic_site || Pleura | imaging_anatomic_site || Pleura | sites_of_involvement || Pleura | treatment_anatomic_sites || Pleura, NOS | progression_or_recurrence_anatomic_site || Pleura, NOS | site_of_resection_or_biopsy || Pleura, NOS | tissue_or_organ_of_origin C156421 || C156422 || C171435 || C173263 || C177570 || C182312 || C70729 site_of_resection_or_biopsy || tissue_or_organ_of_origin || biospecimen_anatomic_site || sites_of_involvement || progression_or_recurrence_anatomic_site || imaging_anatomic_site || treatment_anatomic_sites C C177537 GDC Value Terminology C126271 PI3K p110beta/delta Inhibitor CVL237 A dual selective inhibitor of the beta and delta isoforms of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K-beta/delta), with potential antineoplastic activity. PI3K-beta/delta inhibitor CVL237 selectively inhibits the PI3K-beta and -delta isoforms and prevents their activation, which inhibits PI3K-beta/delta-mediated signal transduction pathways. This decreases proliferation and induces cell death in susceptible tumor cells. Unlike other isoforms of PI3K, PI3K-beta and -delta are overexpressed primarily in solid and hematological tumor cells and play crucial roles in tumor cell survival, and immunoregulation. The targeted inhibition of these PI3Ks allows this agent to potentially be more efficacious and less toxic than pan PI3K inhibitors, which also affect normal, healthy cells. PI3K p110beta/delta Inhibitor KA2237 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C128103 FIGO Stage IIIA1i A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with positive retroperitoneal lymph nodes only. Metastasis equal or less than 10 mm. Stage IIIA1(i) | figo_stage C125738 figo_stage C C177537 GDC Value Terminology C128104 FIGO Stage IIIA1ii A FIGO stage term that applies to ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It refers to cancer with positive retroperitoneal lymph nodes only. Metastasis greater than 10 mm. Stage IIIA1(ii) | figo_stage C125738 figo_stage C C177537 GDC Value Terminology C12903 Supraclavicular Lymph Node A lymph node which is located above the clavicle. Lymph Node(s) Supraclavicular | biospecimen_anatomic_site || Lymph Node(s) Supraclavicular | treatment_anatomic_sites || Lymph Node, Supraclavicular | sites_of_involvement || Supraclavicular | lymph_node_involved_site || Supraclavicular lymph nodes | max_tumor_bulk_site C171435 || C173263 || C188396 || C33027 || C70729 biospecimen_anatomic_site || sites_of_involvement || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_sites C C177537 GDC Value Terminology C129710 BTK Inhibitor TL-895 An orally bioavailable, selective inhibitor of Bruton's tyrosine kinase (BTK), with potential antineoplastic activity. Upon oral administration, BTK inhibitor TL-895 targets and covalently binds to BTK, thereby preventing its activity. This leads to an inhibition of B cell receptor (BCR) signaling and inhibits cell proliferation of B-cell malignancies. BTK, a cytoplasmic tyrosine kinase and member of the Tec family of kinases, plays an important role in B lymphocyte development, activation, signaling, proliferation and survival. BTK Inhibitor M7583 | therapeutic_agents || Tyrosine Kinase Inhibitor TL-895 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C133540 Dapolsertib An orally available inhibitor of PIM family serine/threonine protein kinases and mutant forms of FMS-related tyrosine kinase 3 (FLT3; STK1) with potential antineoplastic activity. Upon oral administration, dapolsertib binds to and inhibits the kinase activities of PIM-1, -2 and -3, and mutant forms of FLT3, which may result in the interruption of the G1/S phase cell cycle transition, an inhibition of cell proliferation, and an induction of apoptosis in tumor cells that overexpress PIMs or express mutant forms of FLT3. FLT3, a tyrosine kinase receptor that is overexpressed or mutated in various cancers, plays a role in signaling pathways that regulate hematopoietic progenitor cell proliferation, and in leukemic cell proliferation and survival. PIM kinases, downstream effectors of many cytokine and growth factor signaling pathways, including the FLT3 signaling pathway, play key roles in cell cycle progression and apoptosis inhibition and may be overexpressed in various malignancies. PIM/FLT3 Kinase Inhibitor SEL24 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C137821 Anti-ASCT2 Antibody-drug Conjugate MEDI7247 An antibody-drug conjugate (ADC) consisting of a human monoclonal antibody against neutral amino acid transporter B(0) (ASCT2; SLC1A5) that is site-specifically conjugated, via a protease-cleavable linker, to the cytotoxic, DNA minor-groove crosslinking agent pyrrolobenzodiazepine (PBD) dimer, with potential antineoplastic activity. Upon administration of anti-ASCT2 ADC MEDI7247, the antibody moiety targets and binds to ASCT2 expressed on cancer cells. Upon antibody/antigen binding, internalization and linker cleavage, the cytotoxic PBD moiety is released. In turn, the imine groups of the PBD moiety bind to the N2 positions of guanines on opposite strands of DNA. This induces DNA strand breaks, inhibits DNA replication, leads to G2/M cell cycle arrest, induces cell death, and inhibits the proliferation of ASCT2-overexpressing tumor cells. ASCT2, a neutral amino acid transporter that mediates the uptake of glutamine, is overexpressed in a variety of cancer cell types. Antibody-drug Conjugate MEDI7247 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C142320 Splenic Lymph Node Any lymph node located along the splenic artery that receives afferent drainage from the pancreas, spleen, and stomach, and which generally has their efferents join the celiac group of preaortic lymph nodes. Lymph Node(s) Splenic | biospecimen_anatomic_site || Lymph Node(s) Splenic | treatment_anatomic_sites || Lymph Node, Splenic | sites_of_involvement || Splenic | lymph_node_involved_site || Splenic lymph nodes | max_tumor_bulk_site C171435 || C173263 || C188396 || C33027 || C70729 biospecimen_anatomic_site || sites_of_involvement || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_sites C C177537 GDC Value Terminology C142330 Hepatitis C Virus RNA Measurement The determination of the amount of hepatitis C virus RNA present in a sample. Hepatitis C Virus RNA | viral_hepatitis_serology_tests C177609 viral_hepatitis_serology_tests C C177537 GDC Value Terminology C15230 Embolization Therapy A procedure in which substances are injected into blood vessels adjacent to a tumor for the purpose of interrupting the blood flow to the cancer cells. Ablation or Embolization, NOS | treatment_type || Embolization | treatment_type C25218 treatment_type C C177537 GDC Value Terminology C155785 Beroterkib Anhydrous The anhydrous form of beroterkib, an orally bioavailable inhibitor of the extracellular signal-regulated kinases (ERK) 1 and 2, with potential antineoplastic activity. Upon administration, beroterkib specifically binds to and inhibits both ERK 1 and 2, thereby preventing the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The MAPK/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in the proliferation, differentiation and survival of tumor cells. ERK 1/2 Inhibitor ASTX029 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C156401 Daratumumab and Recombinant Human Hyaluronidase A co-formulation composed of daratumumab, a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the cell surface glycoprotein cluster of differentiation 38 (CD-38; CD38), and a recombinant form of human hyaluronidase (rHuPH20), with potential antineoplastic activity. Upon subcutaneous administration of daratumumab and hyaluronidase-fihj, daratumumab targets and binds to CD38 on certain CD38-expressing tumors, such as multiple myeloma (MM) and plasma cell leukemia. This binding induces direct apoptosis through Fc-mediated cross-linking and triggers immune-mediated tumor cell lysis through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP) immune responses. CD38, a transmembrane glycoprotein, is expressed in both hematopoietic and non-hematopoietic lineage cells. Hyaluronidase-fihj hydrolyzes and degrades the glycosaminoglycan hyaluronic acid (HA), thereby decreasing interstitial viscosity and enhancing penetration of daratumumab through the interstitial space. This facilitates the delivery of daratumumab to CD38-expressing tumor cells. Daratumumab and Hyaluronidase-fihj | therapeutic_agents || Daratumumab/rHuPH20 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C156701 Zamaporvint An orally available inhibitor of porcupine (PORCN), with potential antineoplastic activity. Upon oral administration, zamaporvint binds to and inhibits PORCN in the endoplasmic reticulum (ER), which blocks post-translational acylation of Wnt ligands and inhibits their secretion. This prevents the activation of Wnt ligands, interferes with Wnt-mediated signaling, and inhibits cell growth in Wnt-driven tumors. Porcupine, a membrane-bound O-acyltransferase (MBOAT), is required for the palmitoylation of Wnt ligands, and plays a key role in Wnt ligand secretion and activity. Wnt signaling is dysregulated in a variety of cancers. Porcupine Inhibitor RXC004 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C156744 Opevesostat An orally bioavailable, non-steroidal, selective inhibitor of the enzyme cytochrome 450 side-chain cleavage (scc) (CYP11A1), with potential antineoplastic activity. Upon oral administration, opevesostat targets, binds to and inhibits the activity of CYP11A1. This prevents the synthesis of all steroid hormones and their precursors. This may inhibit proliferation of hormone-positive tumor cells. CYP11A1, a mitochondrial enzyme, catalyzes the conversion of cholesterol to pregnenolone (Preg), which is the first rate-liming step in steroid hormone biosynthesis. CYP11A1 inhibitor ODM-208 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C156806 New Primary Tumor A finding indicating the development of a tumor in a patient with a history of a previously diagnosed tumor with a different histopathologic profile in another anatomic site as compared to the most recent one. New Primary | tumor_descriptor || Prior primary | classification_of_tumor || Subsequent Primary | classification_of_tumor C166229 || C174459 tumor_descriptor || classification_of_tumor C C177537 GDC Value Terminology C156813 Initial Diagnosis The first diagnosis of the individual's condition. Adulthood | timepoint_category || Initial Diagnosis | initial_disease_status || Initial Diagnosis | timepoint_category C177616 || C198201 initial_disease_status || timepoint_category C C177537 GDC Value Terminology C157062 Ozekibart A recombinant, humanized, agonistic, tetravalent monoclonal antibody directed against human death receptor type 5 (DR5), also called tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2), with potential pro-apoptotic and antineoplastic activities. Upon administration, ozekibart specifically binds to exactly four DR5 receptors per molecule, which mimics the interaction of DR5 with its natural ligand TRAIL. This activates DR5 and the death receptor signaling pathway, which results in the activation of caspase cascades, the induction of tumor cell apoptosis and a reduction in proliferation of DR5-expressing tumor cells. Utilizing a tetravalent monoclonal antibody may overcome the challenge of generating effective DR5 clustering while avoiding toxicities associated with anti-drug antibody (ADA) hyper-clustering. DR5, a member of the TNF receptor superfamily (TNFRSF), is expressed on the surfaces of a variety of tumor cells and plays a key role in the induction of tumor cell apoptosis. Anti-DR5 Agonistic Monoclonal Antibody INBRX-109 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C158083 Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide A preparation of ethylcellulose polymeric nanoparticles loaded with cetuximab, a recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR), and decorated with the somatostatin analog, octreotide, with potential antineoplastic activity. Upon oral administration, the octreotide moiety directs the nanoparticles, which remain inert until a pH of 6.8 is reached, to somatostatin receptors (SSTRs), which are present on the cell membranes of many neuroendocrine tumor (NET) cells. At this pH, cetuximab is selectively released from the ethylcellulose polymer. Cetuximab may then bind to the extracellular domain of EGFR-expressing tumor cells, thereby preventing the activation and subsequent dimerization of the receptor. This may inhibit signal transduction and inhibit tumor cell proliferation in EGFR-dependent tumor cells. EGFR, a member of the EGFR receptor tyrosine kinase family, may be overexpressed on the cell surfaces of various tumor types. Cetuximab-loaded Ethylcellulose Polymeric Nanoparticles Decorated with Octreotide (SY) | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C158533 Autologous Anti-MUC16 CAR-mbIL15-Safety Switch T-cells PRGN-3005 A preparation of autologous T-lymphocytes that have been genetically modified to co-express three transgenes using the Sleeping Beauty (SB) transposon system and include a chimeric antigen receptor (CAR) targeting the unshed portion of the tumor-associated antigen (TAA) human mucin 16 (MUC16, cancer antigen 125; CA125; FLJ14303), a membrane-bound IL-15 (mbIL15) and a safety/kill switch, with potential immunostimulating and antineoplastic activities. Upon introduction of the autologous anti-MUC16 CAR-mbIL15-safety switch T-cells PRGN-3005 into the patient, the T-cells target and bind to MUC16-expressing tumor cells, thereby inducing selective toxicity in MUC16-expressing tumor cells. MUC16, a member of the mucin family of glycoproteins, is overexpressed on a variety of cancer cell types. IL-15 is a pro-survival cytokine that is required for the maintenance of long-lived CD8+ memory T-cells and use of mbIL15 preserves T stem-cell memory (TSCM) through sustained IL-15 signaling, improves T-cell persistence and potentiates the immune response against tumor cells. The safety switch can promote selective elimination of the CAR-T cells. The SB system permits integration of the CAR, the IL-15 fusion variant and safety switch transgenes into T-cells without the need for viral vectors and accelerates the manufacturing process. Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3005 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C158815 Actinium Ac 225-FPI-1434 A radioconjugate consisting of veligrotug, a humanized monoclonal antibody directed against insulin-like growth factor-1 receptor (IGF-1R) linked, via a bifunctional chelate, to the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration of actinium Ac 225-FPI-1434, the veligrotug moiety targets and binds to IGF-1R expressed on tumor cells. Upon binding, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to IGF-1R-expressing tumor cells. Activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by various cancer cell types, stimulates cell proliferation, promotes angiogenesis, enables oncogenic transformation, and suppresses apoptosis. Actinium Ac 225-FPI-1434 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C159498 Imsapepimut A second-generation peptide vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) with potential immunomodulating and antineoplastic activities. Vaccination with imsapepimut may activate the immune system to induce an immune response against IDO-expressing tumor cells. This may restore the proliferation and activation of various immune cells including cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs), and dendritic cells (DCs), and may eradicate IDO-expressing tumor cells through a CTL-mediated response. IDO, a cytosolic enzyme responsible for tryptophan catabolism and conversion of tryptophan into kynurenine, is overexpressed by a variety of tumor cell types and antigen presenting cells (APCs) and plays an important role in immunosuppression mainly through suppression of CTL activation. IDO Peptide Vaccine IO102 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C160847 Autologous Anti-CD33 CAR-mbIL15-Safety Switch T-cells PRGN-3006 A preparation of autologous T-lymphocytes that have been genetically modified to co-express three transgenes using the Sleeping Beauty (SB) transposon system and include a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD33, a membrane-bound IL-15 (mbIL15) and a safety/kill switch, with potential immunostimulating and antineoplastic activities. Upon introduction of the autologous anti-CD33 CAR-mbIL15-safety switch T-cells PRGN-3006 into the patient, the T-cells target and bind to CD33-expressing tumor cells, thereby inducing selective toxicity in CD33-expressing tumor cells. CD33, a myeloid differentiation antigen, is expressed on normal non-pluripotent hematopoietic stem cells and overexpressed on a variety of cancer cell types, including acute myeloid leukemia (AML). It plays a key role in tumor initiation, proliferation and progression. IL-15 is a pro-survival cytokine that is required for the maintenance of long-lived CD8+ memory T-cells and use of mbIL15 preserves T stem-cell memory (TSCM) through sustained IL-15 signaling, improves T-cell persistence and potentiates the immune response against tumor cells. The safety switch can promote selective elimination of the CAR-T cells. The SB system permits integration of the CAR, the IL-15 fusion variant and safety switch transgenes into T-cells without the need for viral vectors and accelerates the manufacturing process. Autologous CAR-mbIL15-Safety Switch T-cells PRGN-3006 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C161599 Anti-SEZ6 Antibody-drug Conjugate ABBV-011 An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against seizure protein 6 homolog (SEZ6) linked to the cytotoxic antitumor antibiotic calicheamicin, with potential antineoplastic activity. Upon administration of anti-SEZ6 ADC ABBV-011, the monoclonal antibody moiety targets and binds to SEZ6 expressed on tumor cells. Upon binding and internalization, calicheamicin is released. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in apoptosis of SEZ6-expressing tumor cells. SEZ6, overexpressed in certain cancers while minimally expressed in normal tissues, plays a role in cell-cell recognition and in neuronal membrane signaling. Antibody-drug Conjugate ABBV-011 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C162010 Soquelitinib An orally available, small-molecule, irreversible inhibitor of interleukin-2 inducible T-cell kinase (ITK) with potential immunomodulatory and antineoplastic activities. Upon oral administration, soquelitinib selectively and covalently binds to the cysteine residue at position 442 (CYS-442) of ITK, thereby disrupting ITK-mediated signal transduction, while sparing tyrosine-protein kinase TXK (resting lymphocyte kinase, RLK) activity. This may abrogate T-cell receptor (TCR) signaling through ITK and inhibit TCR-induced proliferation of malignant T-cells. Additionally, inhibiting ITK activation may prevent the upregulation of GATA-3, a transcription factor that drives T-helper 2 (Th2) cell differentiation and is overexpressed in certain T-cell lymphomas. Thus, selective inhibition of ITK may inhibit Th2 responses without affecting T-helper 1 (Th1)-dependent immunity. ITK, a member of the Tec family of non-receptor protein tyrosine kinases plays a significant role in the T-cell development, differentiation and production of pro-inflammatory cytokines. ITK Inhibitor CPI-818 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C162804 Uzatresgene Autoleucel Autologous human T-lymphocytes transduced with a retroviral vector encoding a T-cell receptor (TCR) specific for the human melanoma antigen A4 (MAGE-A4) and the CD8alpha co-receptor, with potential immunostimulatory and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, uzatresgene autoleucel bind to tumor cells expressing MAGE-A4. This may result in both inhibition of growth and increased cell death of MAGE-A4-expressing tumor cells. The tumor-associated antigen MAGE-A4, a member of the MAGE-A family of cancer testis antigens, is overexpressed by a variety of cancer cell types. Co-expression of CD8alpha may broaden the immune response against tumors and increase antitumor activity by converting CD4+ helper T-cells into CD8+ cytotoxic T-cells. Autologous Genetically-modified MAGE-A4 C1032 CD8alpha T Cells | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C16352 Black or African American Individuals with origins in any of the Black racial groups of Africa, including, for example, African American, Jamaican, Haitian, Nigerian, Ethiopian. and Somali. black or african american | race C17049 race C C177537 GDC Value Terminology C163988 Poly-A Enriched Genomic Library A genomic library where the sample has been subjected to enrichment via binding to immobilized poly-T oligonucleotides, which will preferentially isolate polyadenylated (poly-A) RNAs. Poly-T Enrichment | library_selection C18685 library_selection C C177537 GDC Value Terminology C163989 Randomly Selected Genomic Library A genomic library constructed to generate random DNA fragments by subjecting a genomic sample to either amplification using random primers or fragmentation via exposure to restriction enzymes or shear stress. The fragments can then be cloned or sequenced directly. Random | library_selection C18685 library_selection C C177537 GDC Value Terminology C164024 Sample Procurement Date The date that a sample was collected or obtained. Sample Procurement | index_date || Sample Procurement | timepoint_category C146721 || C198201 index_date || timepoint_category C C177537 GDC Value Terminology C164668 Etentamig A T-cell engaging, human, bispecific, immunoglobulin G4 (IgG4) monoclonal antibody (T-BsAb) directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, etentamig binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. Binding to low-activating CD3 preferentially activates effector over regulatory T-cells and stimulates minimum cytokine release. Anti-alpha BCMA/Anti-alpha CD3 T-cell Engaging Bispecific Antibody TNB-383B | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C165747 CDK8/19 Inhibitor RVU120 An orally bioavailable inhibitor of cyclin-dependent kinases 8 and 19 (CDK8/19), with potential antineoplastic and chemoprotective activities. Upon oral administration, CDK8/19 inhibitor RVU120 targets, binds to and inhibits the activity of CDK8/19, which prevents activation of CDK8/19-mediated oncogenic signaling pathways, blocks selective transcription of various tumor-promoting genes, and inhibits proliferation of CDK8/19-overexpressing tumor cells. CDK8/19, serine/threonine kinases involved in the regulation of the cell cycle, are overexpressed in certain cancer cell types and play key roles in tumor cell proliferation. CDK8/19 Inhibitor SEL 120 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C166409 Sacituzumab Tirumotecan An antibody-drug conjugate (ADC) composed of a monoclonal antibody against tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1) conjugated to an as of yet undisclosed toxin, with potential antineoplastic activity. Upon administration sacituzumab tirumotecan, the anti-TROP2 antibody targets and binds to TROP2 expressed on tumor cells. Upon cellular uptake, the undisclosed toxin exerts, through an as of yet not disclosed mechanism of action, its cytotoxic effect. This inhibits tumor cell proliferation of TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors while its expression is low and/or restricted in normal, healthy tissues; its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival. Anti-TROP2 Antibody-drug Conjugate SKB264 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C167157 KRAS G12C Inhibitor JNJ-74699157 An orally available, small molecule inhibitor of the oncogenic Kirsten rat sarcoma virus homolog KRAS glycine-to-cysteine substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration JNJ-74699157 targets and binds to cytosine 12 within the switch II pocket of GDP-bound KRAS G12C, thereby inhibiting mutant KRAS-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis. KRASG12C Inhibitor JNJ-74699157 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C167210 Enbezotinib An orally bioavailable selective dual inhibitor of fusions and mutations involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (ret) and the src family tyrosine kinases, with potential antineoplastic activity. Upon oral administration, enbezotinib specifically targets and binds to ret mutants and ret-containing fusion products. This results in an inhibition of cell growth of tumor cells that exhibit increased ret activity. By inhibiting src kinase-mediated signaling and reducing the src-initiated recruitment of multiple receptor tyrosine kinases involved in bypass resistance, enbezotinib may be able to overcome tumor resistance which may increase its therapeutic effect. Ret overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of ret tyrosine kinase activity in various cancer cell types; dysregulation of ret activity plays a key role in the development and progression of these cancers. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation, survival, migration, invasion and angiogenesis. Src upregulation is seen in tumors with acquired resistance to RET inhibitors. RET/SRC Inhibitor TPX-0046 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C168580 Xaluritamig A bispecific antibody that simultaneously binds to two different and as of yet undisclosed antigens, with potential immunomodulating and antineoplastic activities. Upon administration, xaluritamig targets and binds to the two antigens. This may modulate the tumor microenvironment (TME) and may enhance an immune-mediated antitumor response. Bispecific Antibody AMG 509 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C168600 Anti-PD-1/CD47 Fusion Protein HX009 A bispecific antibody fusion protein directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the human cell surface antigen CD47, with potential immunostimulating, phagocytosis-inducing and antineoplastic activities. Upon administration of anti-PD-1/CD47 fusion protein HX009, the agent simultaneously and selectively targets and binds to PD-1 expressed on T-lymphocytes and CD47 on tumor cells. The CD47 binding by HX009 blocks the interaction of CD47 with signal regulatory protein alpha (SIRPalpha), an inhibitory protein expressed on macrophages and dendritic cells (DCs), which prevents CD47/SIRPalpha-mediated signaling and abrogates the CD47/SIRPalpha-mediated inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the binding of calreticulin (CRT), which is specifically expressed on the surface of tumor cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed on macrophages, which results in macrophage activation and the specific phagocytosis of the CD47-expressing tumor cells. The binding of HX009 to PD-1 blocks the interaction between PD-1 and its ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore effector T-cell functions and may further activate cytotoxic T-lymphocyte (CTL)-mediated tumor cell killing. CD47, also called integrin-associated protein (IAP), is a tumor-associated antigen (TAA), widely expressed on normal, healthy cells, such as red blood cells and platelets, and overexpressed on the surface of a variety of cancer cells. Expression of CD47, and its interaction with SIRPalpha, leads to the inhibition of macrophage activation and protects cancer cells from phagocytosis, which allows cancer cells to proliferate. By co-targeting CD47 and PD-1, HX009 has the potential to overcome the limitations of existing CD47-targeted therapies by possibly avoiding the side effects caused by binding to CD47 on healthy hematopoietic stem cells (HSCs), which causes unwanted macrophage-mediated phagocytosis. PD-1, an inhibitory receptor belonging to the immunoglobulin superfamily (IgSF), is expressed on activated T-lymphocytes; it functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands, and plays an important role in tumor evasion from host immunity. Anti-PD-1/CD47 Infusion Protein HX009 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C168603 Negalstobart A monoclonal antibody targeting the co-inhibitory receptor lymphocyte-activation gene 3 protein (LAG-3; LAG3; CD223), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, negalstobart targets and binds to LAG-3 expressed by tumor infiltrating lymphocytes (TILs) and blocks the interaction between LAG-3 and major histocompatibility complex class II (MHC II) molecules on the surface of antigen-presenting cells (APCs) and tumor cells. This prevents the negative regulation of T-cell activity that occurs via LAG-3-MHC II binding and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells, leading to a reduction in tumor growth. LAG-3, a member of the immunoglobulin superfamily (IgSF), negatively regulates both the proliferation and activation of T-cells. Its expression on TILs is associated with tumor-mediated immune suppression. Anti-LAG-3 Monoclonal Antibody IBI-110 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C171173 Gruticibart A humanized anti-factor XI (FXI) antibody, with potential anti-thrombotic activity. Upon administration, gruticibart targets and binds to the apple 2 domain of FXI, thereby preventing the binding of FXI to factor XIIa (FXIIa). This blocks factor XIIa-mediated FXI activation without inhibiting FXI activation by thrombin or the procoagulant function of FXIa. The abrogation of FXI activation prolongs the activated partial thromboplastin time (aPTT), and reduces platelet and fibrin accumulation. This results in the inhibition of contact activation-initiated blood coagulation and prevents thrombus formation. FXI contributes to thrombotic disease while playing a limited role in normal hemostasis. Activation of FXI is essential for thrombus growth and stabilization. Xisomab 3G3 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C171381 Fosdesdenosine Sipalabenamide A phosphoramidate derivative of the monophosphate form of cordycepin (3'-deoxyadenosine; 3'-dA), an adenosine derivative first isolated from Cordyceps sinensis, with potential antineoplastic, antioxidant, and anti-inflammatory activities. Upon administration and cellular uptake of fosdesdenosine sipalabenamide by passive diffusion, cordycepin monophosphate (3'-dAMP) is converted into its active anti-cancer metabolite 3'-deoxyadenosine triphosphate (3'-dATP). 3'-dATP functions as a ribonucleoside analogue and competes with ATP during transcription. Therefore, this agent causes RNA synthesis inhibition, inhibits cellular proliferation, and induces apoptosis. Also, 3'-dAMP activates AMP-activated protein kinase (AMPK) and reduces mammalian target of rapamycin (mTOR) signaling. This prevents the hyperphosphorylation of the translation repressor protein 4E-BP1. This results in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase belonging to the phosphatidylinositol 3-kinase (PI3K)-related kinase (PIKK) family, plays an important role in the PI3K/AKT/mTOR signaling pathway that regulates cell growth and proliferation, and its expression or activity is frequently dysregulated in human cancers. Compared to cordycepin alone, the addition of the phosphoramidate moiety may overcome cancer resistance and allow for greater cytotoxicity as fosdesdenosine sipalabenamide does not require a nucleoside transporter for cellular uptake, is independent of enzymatic activation by adenosine kinase (AK) and is not susceptible to enzymatic degradation by adenosine deaminase (ADA). Altogether, this may help overcome cancer resistance to cordycepin. 3'-dA Phosphoramidate NUC-7738 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C171631 Podentamig A recombinant antibody derivative composed of tri-specific T-cell activating construct (TriTAC) directed against the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; TNFRSF17), the epsilon domain of CD3 antigen (CD3e) found on T-lymphocytes, and albumin, with potential immunostimulating and antineoplastic activities. Upon administration, podentamig targets and binds to BCMA on tumor cells and CD3e on cytotoxic T-lymphocytes (CTLs), thereby bringing BCMA-expressing tumor cells and CTLs together, which results in the CTL-mediated cell death of BCMA-expressing tumor cells. The albumin-binding domain targets and binds to serum albumin, thereby extending the serum half-life of podentamig. BCMA, a member of the tumor necrosis factor receptor superfamily (TNFRSF), is overexpressed on malignant plasma cells and plays a key role in plasma cell survival. BCMA/CD3e Tri-specific T-cell Activating Construct HPN217 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C172639 BAP1 Tumor Predisposition Syndrome A syndrome caused by germline mutations in the BAP1 gene. It is inherited in an autosomal dominant pattern. Individuals carrying heterozygous BAP1 mutations have an increased risk of developing various tumor types, most commonly BAP1-inactivated nevi/melanocytomas of the skin, uveal and cutaneous melanomas, peritoneal and pleural mesotheliomas, clear cell renal cell carcinoma, and basal cell carcinoma. (WHO 2018) BAP1 Tumor Predisposition Syndrome | risk_factors C17103 risk_factors C C177537 GDC Value Terminology C172708 Cemacabtagene Ansegedleucel A preparation of allogeneic, frozen, 'off-the-shelf', universal transcription activator-like effector nuclease (TALEN)-engineered, gene-edited T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Using TALEN technology, the T-cell receptor (TCR) alpha chain and CD52 genes are deleted from the CAR19 T-cells. Upon administration, cemacabtagene ansegedleucel specifically targets and binds to CD19-expressing tumor cells, thereby selectively lysing CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Deletion of the CD52 gene makes the modified donor T-cells resistant to the anti-CD52 monoclonal antibody alemtuzumab, which is used during lymphodepletion. The knockout of the TCR alpha gene eliminates TCR expression and is intended to abrogate the potential induction of graft-versus-host disease (GvHD) by the donor T-cells. Allogeneic Anti-CD19 CAR T-cells ALLO-501A | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C172924 Alextatug An engineered, human immunoglobulin (Ig) G1 monoclonal antibody directed against a ribonucleoprotein (RNP) complex, with potential immunostimulating and antineoplastic activities. Upon administration, alextatug targets and binds to its RNP complex antigen on tumor cells. This may activate the innate immune system, change the local tumor microenvironment (TME) and promote T cell-mediated killing of tumor cells. The tumor-restricted RNP complex is expressed in a variety of tumor cells. Anti-Ribonucleoprotein Antibody ATRC-101 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C173374 Masofaniten An orally bioavailable, second-generation inhibitor of the N-terminal domain (NTD) of androgen receptor (AR), with potential antineoplastic activity. Upon oral administration, masofaniten specifically binds to the NTD of AR, thereby inhibiting both AR activation and the AR-mediated signaling pathway. This may inhibit cell growth in AR-overexpressing tumor cells. AR is overexpressed in prostate cancers and is involved in the proliferation, survival and chemoresistance of tumor cells. Masofaniten may be more active and metabolically stable than first-generation AR NTD inhibitors. Androgen Receptor Inhibitor EPI-7386 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C173633 Brimarafenib An orally available inhibitor of both monomer and dimer forms of activating mutations of the serine/threonine-protein kinase BRAF (B-raf) protein, including V600 BRAF mutations, non-V600 BRAF mutations, and RAF fusions, with potential antineoplastic activity. Upon administration, brimarafenib targets and binds to both monomeric and dimeric forms of activating BRAF mutations and fusions. This may result in the inhibition of BRAF-mediated signaling and inhibit proliferation in tumor cells expressing BRAF mutations and fusions. BRAF belongs to the RAF family of serine/threonine protein kinases and plays a role in regulating the mitogen-activated protein kinase (MAPK)/ extracellular signal-regulated kinase (ERK) signaling pathway, which is often dysregulated in human cancers and plays a key role in tumor cell proliferation and survival. BRAF mutations and fusions have been identified in a number of solid tumors and are drivers of cancer growth. BRAF Inhibitor BGB-3245 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C173877 Taniraleucel A population of cryopreserved, off-the-shelf (OTS) allogeneic natural killer (NK) cells derived from human placental hematopoietic stem cells (HSCs) and expressing the CD56 surface antigen and exhibiting a lack of CD3, with potential immunomodulating, antineoplastic and antiviral activities. Upon infusion of taniraleucel, these cells are able to recognize tumor cells as well as virally-infected cells, secrete perforins, granzymes and cytokines, and induce apoptosis in tumor and virally-infected cells. Allogeneic CD56-positive CD3-negative Natural Killer Cells CYNK-001 | therapeutic_agents || Cord Blood-derived Expanded Natural Killer Cells PNK-007 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C173962 Trastuzumab Envedotin An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin G1 (IgG1) a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and site-specifically conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of trastuzumab envedotin, the trastuzumab moiety targets and binds to HER2 on the surface of tumor cells. Following internalization, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. Trastuzumab envedotin has an average drug-to-antibody (DAR) ratio of 2.0; the two MMAE molecules are attached site-specifically through transamidation to residue Q295 in the antibody heavy chain's constant region. Anti-HER2 Antibody-drug Conjugate DP303c | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C174060 Basroparib An orally bioavailable inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme tankyrase, with potential antineoplastic activity. Upon administration, basroparib selectively binds to and inhibits the activity of tankyrase. This may block the tankyrase-mediated poly(ADP-ribosyl)ation of multiple target proteins including various tumor suppressors. This may include the blockage of the poly(ADP-ribosyl)ation and destabilization of AXIN, a negative regulator of beta-catenin, and prevents Wnt/beta-catenin signaling. This may inhibit the activation of transcription of a wide range of target genes of Wnt/beta-catenin signaling, thereby preventing gene expression of many Wnt-related, pro-survival proteins and suppressing tumor cell growth. Tankyrase, a member of the PARP family, plays an important role in the regulation of the Wnt/beta-catenin signaling pathway, tumor suppressors, as well as telomere maintenance and mitosis regulation. Tankyrase Inhibitor STP1002 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C174169 Lucicebtide A peptide antagonist of the transcription factor CCAAT/enhancer-binding protein beta (C/EBP beta), with potential antineoplastic activity. Upon administration, lucicebtide targets and inhibits the activity of C/EBP beta. This prevents the expression of C/EBP beta target genes and proteins, including the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), cyclins and inhibitor of differentiation (ID) family of proteins, which are involved in cell proliferation, differentiation, and cell cycle regulation. This may lead to apoptosis in tumor cells. C/EBP beta is overexpressed in many cancers and plays an important role in the regulation of cell differentiation; its expression is associated with tumor cell survival and proliferation. C/EBP Beta Antagonist ST101 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C174395 Misitatug Blivedotin An antibody-drug conjugate (ADC) composed of an antibody directed against the human cell surface glycoprotein mesothelin and conjugated, via a cleavable linker, to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of misitatug blivedotin, the antibody moiety targets and binds to the tumor associated antigen (TAA) mesothelin on the surface of tumor cells. Upon internalization and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in mesothelin-expressing tumor cells. Mesothelin is overexpressed by all mesotheliomas and a variety of other cancers, while it is minimally expressed in normal tissue. Anti-mesothelin/MMAE Antibody-drug Conjugate RC88 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C174412 BCMA-CD19 Compound CAR T Cells A preparation of T-lymphocytes transduced with a lentiviral vector expressing a compound chimeric antigen receptor (cCAR) containing two distinct units of CARs, one specific for the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and one specific for the TAA CD19, with potential immunomodulating and antineoplastic activities. Upon administration, the BCMA-CD19 cCAR T cells specifically and simultaneously target and bind to tumor cells expressing BCMA and/or CD19. This induces selective toxicity in tumor cells that express BCMA and/or CD19. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in the survival of B-lymphocytes and plasma cells. BCMA is found on the surfaces of B-cells and is overexpressed on malignant plasma cells. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage malignancies. Targeting two different antigens may improve coverage and protect against antigen escape and relapse as it is less likely for tumor cells to lose both antigens. BCMA-CD19 Compound CAR T Cells | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C17459 Hispanic or Latino Includes individuals of Mexican, Puerto Rican, Salvadoran, Cuban, Dominican, Guatemalan, and other Central or South American or Spanish culture or origin. hispanic or latino | ethnicity C16564 ethnicity C C177537 GDC Value Terminology C175251 Tagtociclib An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon administration, tagtociclib selectively targets, binds to and inhibits the activity of CDK2. This may lead to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDKs are serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation and are frequently overexpressed in tumor cells. CDK2/cyclin E complex plays an important role in retinoblastoma (Rb) protein phosphorylation and the G1-S phase cell cycle transition. CDK2/cyclin A complex plays an important role in DNA synthesis in S phase and the activation of CDK1/cyclin B for the G2-M phase cell cycle transition. CDK2 Inhibitor PF-07104091 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C175453 Gimistotug An agonistic monoclonal antibody targeting the co-stimulatory receptor OX40 (CD134; tumor necrosis factor receptor superfamily member 4; TNFRSF4), with potential immunostimulatory and antineoplastic activities. Upon administration, gimistotug selectively binds to OX40, thereby activating OX40. This induces the proliferation of memory and effector T-lymphocytes and results in a T-cell-mediated immune response against tumor cells, which leads to tumor cell lysis. OX40, a cell surface glycoprotein and member of the tumor necrosis factor receptor superfamily (TNFRSF), is expressed on T-lymphocytes and provides a co-stimulatory signal that promotes both the proliferation and survival of activated T-cells. Anti-OX40 Agonist Monoclonal Antibody BGB-A445 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C175512 Emidurdar An orally bioavailable inhibitor of the serine/arginine-rich splicing factor protein kinase 1 (SRPK1) and the ATP-binding cassette sub-family G member 2 (ABCG2), with potential chemosensitizing and antineoplastic activities. Upon oral administration, emidurdar targets, binds to and inhibits the activity of SRPK1 and ABCG2. Inhibition of the cellular efflux pump ABCG2 by emidurdar prevents the efflux of co-administered chemotherapeutic agents from cancer cells. This may abrogate cancer cell drug resistance and may re-sensitize cancer cells to the chemotherapeutic agents. Inhibition of SRPK1 kinase by emidurdar inhibits the SRPK1-mediated phosphorylation of splicing factors rich in serine/arginine domains, thereby inhibiting the activation of proteins that are involved in the regulation of alternative splicing. This may inhibit cancer cell proliferation. SRPK1 is upregulated in various cancer cell types. Its upregulation is correlated with higher tumor staging, grading, and shorter survival. SRPK1/ABCG2 Inhibitor SCO-101 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C175542 Crelosidenib An orally available inhibitor of mutant form of the isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble), including the substitution mutation at arginine (R) in position 132, IDH1(R132), with potential antineoplastic activity. Upon oral administration, crelosidenib specifically and covalently binds to and modifies a single cysteine (Cys269) in the allosteric binding pocket of mutant forms of IDH1, thereby inactivating IDH1. This inhibits the formation of the oncometabolite 2-hydroxyglutarate (2HG) from alpha-ketoglutarate (a-KG). This depletes 2-HG levels, prevents 2HG-mediated signaling and leads to both an induction of cellular differentiation and an inhibition of cellular proliferation in tumor cells expressing mutant forms of IDH1. In addition, crelosidenib has the ability to cross the blood-brain barrier (BBB). IDH1 mutations, including IDH1(R132) mutations, are highly expressed in certain malignancies, including gliomas; they initiate and drive cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG. IDH1 Mutant Inhibitor LY3410738 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C17649 Other Different than the one(s) previously specified or mentioned. Other | additional_pathology_findings || Other | alcohol_type || Other | ann_arbor_b_symptoms_described || Other | biospecimen_anatomic_site || Other | comorbidities || Other | diabetes_treatment_type || Other | dysplasia_type || Other | embolic_agent || Other | first_event || Other | immunosuppressive_treatment_type || Other | instrument_model || Other | library_selection || Other | max_tumor_bulk_site || Other | method_of_diagnosis || Other | method_of_sample_procurement || Other | molecular_analysis_method || Other | occupation_type || Other | platform || Other | reason_treatment_ended || Other | relationship_type || Other | sites_of_involvement || Other | therapeutic_agents || Other | timepoint_category || Other | treatment_anatomic_sites || Other | treatment_type || Other | type_of_tobacco_used || Other | variant_type || other | classification_of_tumor || other | race C158809 || C16457 || C166276 || C17049 || C171435 || C173263 || C173544 || C174459 || C177576 || C177610 || C177629 || C18685 || C188396 || C1909 || C19770 || C198107 || C198201 || C25193 || C25218 || C4086 || C43283 || C45378 || C45902 || C574 || C70700 || C70729 || C83393 || C97229 || C99532 additional_pathology_findings || comorbidities || reason_treatment_ended || race || biospecimen_anatomic_site || sites_of_involvement || variant_type || classification_of_tumor || method_of_diagnosis || instrument_model || type_of_tobacco_used || library_selection || max_tumor_bulk_site || therapeutic_agents || molecular_analysis_method || first_event || timepoint_category || occupation_type || treatment_type || dysplasia_type || ann_arbor_b_symptoms_described || platform || alcohol_type || immunosuppressive_treatment_type || method_of_sample_procurement || treatment_anatomic_sites || relationship_type || embolic_agent || diabetes_treatment_type C C177537 GDC Value Terminology C176980 Superficial Atypical Lipomatous Tumor A locally aggressive mesenchymal neoplasm of a superficial body structure that is characterized by the presence of an adipocytic proliferation exhibiting at least focal nuclear atypia in both adipocytes and stromal cells. Amplification of MDM2 and/or CDK4 is almost always present. Superficial well differentiated liposarcoma | primary_diagnosis || Well differentiated liposarcoma of superficial soft tissue | primary_diagnosis C177621 primary_diagnosis C C177537 GDC Value Terminology C17998 Unknown Not known, observed, recorded; or reported as unknown by the data contributor. Unknown | adapter_content || Unknown | adrenal_hormone || Unknown | adverse_event || Unknown | adverse_event_grade || Unknown | ajcc_clinical_m || Unknown | ajcc_clinical_n || Unknown | ajcc_clinical_stage || Unknown | ajcc_clinical_t || Unknown | ajcc_pathologic_m || Unknown | ajcc_pathologic_n || Unknown | ajcc_pathologic_stage || Unknown | ajcc_pathologic_t || Unknown | ajcc_staging_system_edition || Unknown | alcohol_frequency || Unknown | alcohol_history || Unknown | alcohol_intensity || Unknown | alcohol_type || Unknown | anaplasia_present || Unknown | anaplasia_present_type || Unknown | aneuploidy || Unknown | ann_arbor_b_symptoms || Unknown | ann_arbor_b_symptoms_described || Unknown | ann_arbor_clinical_stage || Unknown | ann_arbor_extranodal_involvement || Unknown | ann_arbor_pathologic_stage || Unknown | antigen || Unknown | asbestos_exposure_type || Unknown | barretts_esophagus_goblet_cells_present || Unknown | basic_statistics || Unknown | best_overall_response || Unknown | biospecimen_anatomic_site || Unknown | biospecimen_laterality || Unknown | biospecimen_type || Unknown | bone_marrow_malignant_cells || Unknown | burkitt_lymphoma_clinical_variant || Unknown | calgb_risk_group || Unknown | cancer_detection_method || Unknown | cause_of_death || Unknown | cause_of_death_source || Unknown | cdc_hiv_risk_factors || Unknown | chemical_exposure_type || Unknown | chemo_concurrent_to_radiation || Unknown | child_pugh_classification || Unknown | chipseq_antibody || Unknown | chipseq_target || Unknown | chromosomal_translocation || Unknown | chromosome || Unknown | chromosome_arm || Unknown | clark_level || Unknown | classification_of_tumor || Unknown | clonality || Unknown | cog_liver_stage || Unknown | cog_neuroblastoma_risk_group || Unknown | cog_renal_stage || Unknown | cog_rhabdomyosarcoma_risk_group || Unknown | columnar_mucosa_present || Unknown | comorbidities || Unknown | comorbidity_method_of_diagnosis || Unknown | consistent_pathology_review || Unknown | contiguous_organ_invaded || Unknown | country_of_birth || Unknown | country_of_residence_at_enrollment || Unknown | diabetes_treatment_type || Unknown | diagnosis_pathologically_confirmed || Unknown | disease_response || Unknown | disease_type || Unknown | distance_normal_to_tumor || Unknown | double_expressor_lymphoma || Unknown | double_hit_lymphoma || Unknown | drug_category || Unknown | dysplasia_degree || Unknown | dysplasia_type || Unknown | ecog_performance_status || Unknown | education_level || Unknown | eln_risk_classification || Unknown | embolic_agent || Unknown | enneking_msts_grade || Unknown | enneking_msts_metastasis || Unknown | enneking_msts_stage || Unknown | enneking_msts_tumor_site || Unknown | ensat_clinical_m || Unknown | ensat_pathologic_n || Unknown | ensat_pathologic_stage || Unknown | ensat_pathologic_t || Unknown | environmental_tobacco_smoke_exposure || Unknown | esophageal_columnar_dysplasia_degree || Unknown | esophageal_columnar_metaplasia_present || Unknown | ethnicity || Unknown | evidence_of_progression_type || Unknown | evidence_of_recurrence_type || Unknown | exposure_duration || Unknown | exposure_source || Unknown | exposure_type || Unknown | extracapsular_extension || Unknown | extracapsular_extension_present || Unknown | extranodal_extension || Unknown | extrathyroid_extension || Unknown | eye_color || Unknown | figo_stage || Unknown | first_event || Unknown | first_symptom_prior_to_diagnosis || Unknown | fragmentation_enzyme || Unknown | gastric_esophageal_junction_involvement || Unknown | gene_symbol || Unknown | gleason_grade_group || Unknown | gleason_grade_tertiary || Unknown | goblet_cells_columnar_mucosa_present || Unknown | haart_treatment_indicator || Unknown | hepatitis_sustained_virological_response || Unknown | histologic_progression_type || Unknown | histone_family || Unknown | histone_variant || Unknown | history_of_tumor || Unknown | history_of_tumor_type || Unknown | hormonal_contraceptive_type || Unknown | hormonal_contraceptive_use || Unknown | hormonal_replacement_therapy_status || Unknown | hormone_replacement_therapy_type || Unknown | hpv_strain || Unknown | hysterectomy_margins_involved || Unknown | hysterectomy_type || Unknown | igcccg_stage || Unknown | imaging_anatomic_site || Unknown | imaging_findings || Unknown | imaging_result || Unknown | imaging_type || Unknown | immunosuppressive_treatment_type || Unknown | initial_disease_status || Unknown | inpc_grade || Unknown | inpc_histologic_group || Unknown | inrg_stage || Unknown | inss_stage || Unknown | instrument_model || Unknown | international_prognostic_index || Unknown | irs_group || Unknown | irs_stage || Unknown | ishak_fibrosis_score || Unknown | iss_stage || Unknown | karnofsky_performance_status || Unknown | kmer_content || Unknown | laboratory_test || Unknown | largest_extrapelvic_peritoneal_focus || Unknown | laterality || Unknown | lost_to_followup || Unknown | lymph_node_dissection_site || Unknown | lymph_node_involved_site || Unknown | lymph_node_involvement || Unknown | lymph_nodes_removed || Unknown | lymphatic_invasion_present || Unknown | margin_status || Unknown | margins_involved_site || Unknown | marital_status || Unknown | masaoka_stage || Unknown | measurement_type || Unknown | measurement_unit || Unknown | medulloblastoma_molecular_classification || Unknown | melanoma_known_primary || Unknown | menopause_status || Unknown | metaplasia_present || Unknown | metastasis_at_diagnosis || Unknown | method_of_diagnosis || Unknown | method_of_sample_procurement || Unknown | micrometastasis_present || Unknown | micropapillary_features || Unknown | mismatch_repair_mutation || Unknown | mitosis_karyorrhexis_index || Unknown | molecular_analysis_method || Unknown | molecular_consequence || Unknown | morphologic_architectural_pattern || Unknown | morphology || Unknown | mutation_codon || Unknown | necrosis_present || Unknown | non_nodal_regional_disease || Unknown | non_nodal_tumor_deposits || Unknown | nononcologic_therapeutic_agents || Unknown | normal_tumor_genotype_snp_match || Unknown | number_of_pregnancies || Unknown | occupation_type || Unknown | ovarian_specimen_status || Unknown | ovarian_surface_involvement || Unknown | overrepresented_sequences || Unknown | oxygen_use_indicator || Unknown | oxygen_use_type || Unknown | parent_with_radiation_exposure || Unknown | pathogenicity || Unknown | per_base_n_content || Unknown | per_base_sequence_content || Unknown | per_base_sequence_quality || Unknown | per_sequence_gc_content || Unknown | per_sequence_quality_score || Unknown | per_tile_sequence_quality || Unknown | perineural_invasion_present || Unknown | peripancreatic_lymph_nodes_positive || Unknown | peritoneal_fluid_cytological_status || Unknown | peritoneal_washing_results || Unknown | ploidy || Unknown | prcc_type || Unknown | pregnancy_outcome || Unknown | pregnant_at_diagnosis || Unknown | premature_at_birth || Unknown | prescribed_dose_units || Unknown | preservation_method || Unknown | primary_diagnosis || Unknown | primary_gleason_grade || Unknown | primary_site || Unknown | prior_treatment || Unknown | procedures_performed || Unknown | progression_or_recurrence || Unknown | progression_or_recurrence_anatomic_site || Unknown | progression_or_recurrence_type || Unknown | protocol_identifier || Unknown | race || Unknown | radiosensitizing_agent || Unknown | reason_treatment_ended || Unknown | reason_treatment_not_given || Unknown | reflux_treatment_type || Unknown | relationship_primary_diagnosis || Unknown | relationship_type || Unknown | relative_deceased || Unknown | relative_smoker || Unknown | residual_disease || Unknown | residual_tumor || Unknown | residual_tumor_measurement || Unknown | rhabdoid_present || Unknown | risk_factor_method_of_diagnosis || Unknown | risk_factor_treatment || Unknown | risk_factors || Unknown | sarcomatoid_present || Unknown | satellite_nodule_present || Unknown | scan_tracer_used || Unknown | second_gene_symbol || Unknown | secondary_gleason_grade || Unknown | secondhand_smoke_as_child || Unknown | sequence_duplication_levels || Unknown | sequence_length_distribution || Unknown | site_of_resection_or_biopsy || Unknown | sites_of_involvement || Unknown | smoking_frequency || Unknown | specimen_type || Unknown | staining_intensity_scale || Unknown | staining_intensity_value || Unknown | supratentorial_localization || Unknown | synchronous_malignancy || Unknown | target_capture_kit || Unknown | test_analyte_type || Unknown | test_result || Unknown | test_units || Unknown | therapeutic_agents || Unknown | therapeutic_levels_achieved || Unknown | therapeutic_target_level || Unknown | time_between_waking_and_first_smoke || Unknown | timepoint_category || Unknown | tissue_or_organ_of_origin || Unknown | tissue_type || Unknown | tobacco_smoking_status || Unknown | transglottic_extension || Unknown | treatment_anatomic_sites || Unknown | treatment_dose_units || Unknown | treatment_effect || Unknown | treatment_effect_indicator || Unknown | treatment_emergent_adverse_event || Unknown | treatment_frequency || Unknown | treatment_intent_type || Unknown | treatment_outcome || Unknown | treatment_type || Unknown | tumor_confined_to_organ_of_origin || Unknown | tumor_depth_descriptor || Unknown | tumor_descriptor || Unknown | tumor_focality || Unknown | tumor_grade || Unknown | tumor_grade_category || Unknown | tumor_infiltrating_lymphocytes || Unknown | tumor_infiltrating_macrophages || Unknown | tumor_regression_grade || Unknown | tumor_shape || Unknown | type_of_smoke_exposure || Unknown | uicc_clinical_m || Unknown | uicc_clinical_n || Unknown | uicc_clinical_stage || Unknown | uicc_clinical_t || Unknown | uicc_pathologic_m || Unknown | uicc_pathologic_n || Unknown | uicc_pathologic_stage || Unknown | uicc_pathologic_t || Unknown | uicc_staging_system_edition || Unknown | ulceration_indicator || Unknown | undescended_testis_corrected || Unknown | undescended_testis_corrected_laterality || Unknown | undescended_testis_corrected_method || Unknown | undescended_testis_history || Unknown | undescended_testis_history_laterality || Unknown | variant_origin || Unknown | variant_type || Unknown | vascular_invasion_present || Unknown | vascular_invasion_type || Unknown | viral_hepatitis_serology_tests || Unknown | vital_status || Unknown | weiss_assessment_findings || Unknown | weiss_assessment_score || Unknown | wgs_coverage || Unknown | who_cns_grade || Unknown | who_nte_grade || Unknown | wilms_tumor_histologic_subtype || Unknown | zygosity || unknown | gender || unknown | prior_malignancy || unknown | progression_or_recurrence || unknown | relationship_gender || unknown | relative_with_cancer_history || unknown | treatment_or_therapy || unknown | vital_status C102562 || C102704 || C104014 || C104015 || C104017 || C104018 || C104023 || C104027 || C105721 || C106304 || C106317 || C106541 || C106551 || C111073 || C112400 || C121007 || C123560 || C125738 || C125904 || C126378 || C127762 || C127768 || C127772 || C129439 || C13202 || C132299 || C133427 || C13355 || C133706 || C138899 || C139007 || C139577 || C140258 || C140259 || C140262 || C140266 || C141342 || C142346 || C143151 || C15256 || C154881 || C15599 || C156421 || C156422 || C157103 || C157110 || C157233 || C157410 || C157425 || C157437 || C158874 || C159229 || C159643 || C159824 || C160720 || C160827 || C160837 || C160996 || C16124 || C161320 || C16165 || C162221 || C164057 || C16457 || C164683 || C16515 || C16564 || C166199 || C166229 || C166276 || C16687 || C168796 || C17001 || C17049 || C17103 || C171253 || C17140 || C171435 || C173263 || C173544 || C17357 || C173595 || C17369 || C174459 || C175524 || C176287 || C176708 || C176985 || C177549 || C177550 || C177555 || C177556 || C177557 || C177558 || C177559 || C177561 || C177562 || C177564 || C177565 || C177566 || C177567 || C177568 || C177569 || C177570 || C177571 || C177572 || C177576 || C177577 || C177578 || C177579 || C177583 || C177585 || C177586 || C177587 || C177588 || C177589 || C177590 || C177591 || C177592 || C177593 || C177594 || C177595 || C177596 || C177597 || C177598 || C177599 || C177600 || C177601 || C177602 || C177603 || C177604 || C177605 || C177606 || C177607 || C177608 || C177609 || C177610 || C177611 || C177612 || C177613 || C177614 || C177616 || C177619 || C177620 || C177621 || C177622 || C177624 || C177626 || C177627 || C177628 || C177630 || C177631 || C177632 || C177633 || C177634 || C177635 || C177636 || C177637 || C177638 || C177640 || C177641 || C178243 || C178276 || C178286 || C178287 || C178288 || C178289 || C17953 || C181720 || C181723 || C182060 || C182097 || C182099 || C182101 || C182102 || C182109 || C182312 || C18304 || C185074 || C185264 || C185265 || C185266 || C185267 || C185268 || C185269 || C185270 || C185271 || C185272 || C185273 || C185274 || C185275 || C188000 || C188372 || C188373 || C188388 || C188406 || C188408 || C188409 || C188411 || C188415 || C188429 || C188446 || C188448 || C18849 || C18919 || C1909 || C19232 || C19697 || C19770 || C19796 || C198091 || C198092 || C198095 || C198101 || C198107 || C198127 || C198131 || C198139 || C198194 || C198195 || C198198 || C198200 || C198201 || C198204 || C198206 || C199145 || C200441 || C200442 || C200444 || C200446 || C200469 || C200470 || C200473 || C200474 || C200476 || C200477 || C20118 || C202137 || C202138 || C202139 || C202140 || C202155 || C202157 || C202158 || C202159 || C202160 || C206478 || C206479 || C206480 || C2480 || C25185 || C25188 || C25193 || C25218 || C25294 || C25717 || C268 || C28013 || C28076 || C2873 || C29878 || C2991 || C33027 || C3420 || C35529 || C35886 || C36037 || C36292 || C38032 || C39694 || C4086 || C41331 || C42578 || C43283 || C45824 || C45902 || C4809 || C48603 || C48604 || C48605 || C49236 || C50995 || C54398 || C574 || C67415 || C70700 || C70713 || C70729 || C81180 || C81229 || C81239 || C83280 || C83315 || C83393 || C85416 || C89081 || C90491 || C92808 || C93431 || C93711 || C94536 || C94811 || C95149 || C97229 || C97926 || C99532 inpc_grade || reason_treatment_not_given || weiss_assessment_score || weiss_assessment_findings || ensat_pathologic_stage || ensat_pathologic_t || ensat_pathologic_n || ensat_clinical_m || ecog_performance_status || tumor_regression_grade || mitosis_karyorrhexis_index || menopause_status || number_of_pregnancies || igcccg_stage || premature_at_birth || child_pugh_classification || margin_status || figo_stage || double_hit_lymphoma || alcohol_intensity || staining_intensity_value || perineural_invasion_present || vascular_invasion_present || medulloblastoma_molecular_classification || chromosome || protocol_identifier || inrg_stage || chromosome_arm || mismatch_repair_mutation || double_expressor_lymphoma || iss_stage || residual_tumor || enneking_msts_stage || enneking_msts_grade || enneking_msts_tumor_site || enneking_msts_metastasis || chemo_concurrent_to_radiation || gleason_grade_group || masaoka_stage || hysterectomy_type || ulceration_indicator || hormone_replacement_therapy_type || site_of_resection_or_biopsy || tissue_or_organ_of_origin || exposure_type || hpv_strain || first_symptom_prior_to_diagnosis || hormonal_contraceptive_use || tumor_focality || eye_color || primary_site || calgb_risk_group || lymph_nodes_removed || lost_to_followup || lymphatic_invasion_present || satellite_nodule_present || extranodal_extension || transglottic_extension || prior_treatment || synchronous_malignancy || haart_treatment_indicator || metastasis_at_diagnosis || type_of_smoke_exposure || comorbidities || treatment_emergent_adverse_event || fragmentation_enzyme || ethnicity || treatment_dose_units || tumor_descriptor || reason_treatment_ended || histone_family || pathogenicity || ploidy || race || risk_factors || second_gene_symbol || environmental_tobacco_smoke_exposure || biospecimen_anatomic_site || sites_of_involvement || variant_type || gender || gene_symbol || imaging_type || classification_of_tumor || peritoneal_fluid_cytological_status || cause_of_death_source || imaging_result || morphology || irs_group || irs_stage || ajcc_clinical_stage || ajcc_pathologic_stage || test_analyte_type || ann_arbor_clinical_stage || ann_arbor_pathologic_stage || ajcc_staging_system_edition || eln_risk_classification || comorbidity_method_of_diagnosis || inpc_histologic_group || who_cns_grade || who_nte_grade || wilms_tumor_histologic_subtype || margins_involved_site || progression_or_recurrence_anatomic_site || supratentorial_localization || distance_normal_to_tumor || method_of_diagnosis || evidence_of_recurrence_type || dysplasia_degree || country_of_residence_at_enrollment || target_capture_kit || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || burkitt_lymphoma_clinical_variant || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || hysterectomy_margins_involved || metaplasia_present || necrosis_present || non_nodal_regional_disease || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || ovarian_surface_involvement || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || variant_origin || biospecimen_laterality || ajcc_clinical_m || ajcc_pathologic_m || ovarian_specimen_status || viral_hepatitis_serology_tests || instrument_model || ajcc_clinical_n || ajcc_pathologic_n || chipseq_antibody || chipseq_target || initial_disease_status || pregnant_at_diagnosis || histone_variant || primary_diagnosis || relationship_gender || cdc_hiv_risk_factors || secondhand_smoke_as_child || smoking_frequency || time_between_waking_and_first_smoke || cog_liver_stage || cog_neuroblastoma_risk_group || cog_renal_stage || cog_rhabdomyosarcoma_risk_group || hepatitis_sustained_virological_response || ajcc_clinical_t || ajcc_pathologic_t || reflux_treatment_type || treatment_effect_indicator || progression_or_recurrence_type || esophageal_columnar_dysplasia_degree || relationship_primary_diagnosis || peripancreatic_lymph_nodes_positive || anaplasia_present || anaplasia_present_type || vascular_invasion_type || largest_extrapelvic_peritoneal_focus || education_level || consistent_pathology_review || undescended_testis_corrected_laterality || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || undescended_testis_corrected_method || undescended_testis_history_laterality || adrenal_hormone || imaging_anatomic_site || clonality || history_of_tumor_type || adapter_content || basic_statistics || kmer_content || overrepresented_sequences || per_base_n_content || per_base_sequence_content || per_base_sequence_quality || per_sequence_gc_content || per_sequence_quality_score || per_tile_sequence_quality || sequence_duplication_levels || sequence_length_distribution || alcohol_frequency || exposure_source || asbestos_exposure_type || drug_category || uicc_clinical_m || uicc_clinical_n || uicc_clinical_stage || uicc_clinical_t || uicc_pathologic_m || uicc_pathologic_n || uicc_pathologic_stage || uicc_pathologic_t || history_of_tumor || prior_malignancy || treatment_outcome || therapeutic_agents || preservation_method || tissue_type || molecular_analysis_method || tobacco_smoking_status || cancer_detection_method || chemical_exposure_type || evidence_of_progression_type || extracapsular_extension || first_event || lymph_node_dissection_site || mutation_codon || peritoneal_washing_results || residual_tumor_measurement || risk_factor_method_of_diagnosis || therapeutic_levels_achieved || therapeutic_target_level || timepoint_category || tumor_grade_category || uicc_staging_system_edition || imaging_findings || country_of_birth || contiguous_organ_invaded || measurement_type || melanoma_known_primary || relative_smoker || wgs_coverage || tumor_depth_descriptor || tumor_shape || tumor_infiltrating_lymphocytes || tumor_infiltrating_macrophages || international_prognostic_index || extracapsular_extension_present || extrathyroid_extension || histologic_progression_type || micrometastasis_present || nononcologic_therapeutic_agents || oxygen_use_indicator || oxygen_use_type || radiosensitizing_agent || staining_intensity_scale || prescribed_dose_units || hormonal_replacement_therapy_status || prcc_type || scan_tracer_used || laterality || marital_status || occupation_type || treatment_type || laboratory_test || vital_status || antigen || karnofsky_performance_status || tumor_grade || aneuploidy || relative_with_cancer_history || disease_type || lymph_node_involved_site || chromosomal_translocation || lymph_node_involvement || morphologic_architectural_pattern || tumor_confined_to_organ_of_origin || test_result || treatment_effect || sarcomatoid_present || dysplasia_type || adverse_event || measurement_unit || ann_arbor_b_symptoms_described || zygosity || alcohol_type || residual_disease || primary_gleason_grade || secondary_gleason_grade || gleason_grade_tertiary || treatment_or_therapy || disease_response || treatment_intent_type || immunosuppressive_treatment_type || test_units || method_of_sample_procurement || specimen_type || treatment_anatomic_sites || relative_deceased || alcohol_history || cause_of_death || exposure_duration || biospecimen_type || relationship_type || inss_stage || treatment_frequency || pregnancy_outcome || hormonal_contraceptive_type || procedures_performed || adverse_event_grade || best_overall_response || clark_level || ishak_fibrosis_score || embolic_agent || molecular_consequence || diabetes_treatment_type C C177537 GDC Value Terminology C18063 Gray A SI derived unit of absorbed radiation dose. One gray is equal to an absorbed dose of one joule per kilogram of matter, or to 100 rads. Gy | prescribed_dose_units || Gy | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C18206 Distant Metastasis A biological process that involves the transfer and growth of cancer cells from the site of the primary tumor. Relocation of malignant cells during metastasis can be restricted to movement within a specific tissue/organ or may entail migration to a distal locus within the body. This phenotype is a characteristic of all malignant tumors. Distant Metastasis | imaging_findings || Distant Metastasis | metastasis_at_diagnosis C162221 || C199145 metastasis_at_diagnosis || imaging_findings C C177537 GDC Value Terminology C188218 Neuroendocrine Tumor A well-differentiated neuroendocrine neoplasm of low, intermediate, or high grade. 8240/3 | morphology || 8241/3 | morphology || 8248/1 | morphology || Apudoma | primary_diagnosis || Carcinoid tumor, NOS | primary_diagnosis || Carcinoid, NOS | primary_diagnosis || Enterochromaffin cell carcinoid | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C198747 Government Regulatory Associate Professional Occupations held by individuals who work with customs and border inspectors, government tax and excise officials, government social benefits, government licensing, police inspectors and detectives, government regulatory associate professionals. Government Regulatory Associate Professionals | occupation_type C25193 occupation_type C C177537 GDC Value Terminology C20985 Ablation Therapy Removal, separation, detachment, extirpation, or eradication of a body part, pathway, or function by surgery, chemical destruction, morbid process, or noxious substance. Ablation or Embolization, NOS | treatment_type || Ablation, NOS | treatment_type C25218 treatment_type C C177537 GDC Value Terminology C26323 Hematopoietic and Lymphoid Cell Disorder A non-neoplastic or neoplastic disorder that arises from the hematopoietic and lymphoid cells. Representative examples include disorders that affect the synthesis of hemoglobin, coagulation disorders, leukemias, and lymphomas. Hematologic Disorder, NOS | risk_factors C17103 risk_factors C C177537 GDC Value Terminology C26712 Mucinous Adenocarcinoma An invasive adenocarcinoma composed of malignant glandular cells that contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland. 8480/3 | morphology || Colloid adenocarcinoma | primary_diagnosis || Colloid carcinoma | primary_diagnosis || Gelatinous adenocarcinoma | primary_diagnosis || Gelatinous carcinoma | primary_diagnosis || Mucinous adenocarcinoma | primary_diagnosis || Mucinous carcinoma | primary_diagnosis || Mucoid adenocarcinoma | primary_diagnosis || Mucoid carcinoma | primary_diagnosis || Mucous adenocarcinoma | primary_diagnosis || Mucous carcinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C27007 Spitz Nevus An acquired or congenital benign skin melanocytic neoplasm. It can occur on any area of the body, but most commonly occurs on the face of children and the thighs of young females. It is characterized by a proliferation of large spindle, oval, or large epithelioid melanocytes in the dermal-epidermal junction. The melanocytic proliferation subsequently extends into the dermis. 8770/0 | morphology || Epithelioid and spindle cell nevus | primary_diagnosis || Juvenile melanoma | primary_diagnosis || Juvenile nevus | primary_diagnosis || Spindle cell nevus, NOS | primary_diagnosis || Spitz nevus | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C27091 Malignant Spindle Cell Neoplasm A neoplasm characterized by the presence of malignant spindle cells. 8004/3 | morphology || Malignant tumor, fusiform cell type | primary_diagnosis || Malignant tumor, spindle cell type | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C27134 Hematopoietic and Lymphoid Cell Neoplasm A neoplasm that arises from hematopoietic and lymphoid cells. Representative examples include myeloproliferative neoplasms, myelodysplastic syndromes, leukemias, Hodgkin lymphomas, and non-Hodgkin lymphomas. Hematologic Cancer | relationship_primary_diagnosis C178243 relationship_primary_diagnosis C C177537 GDC Value Terminology C27273 Poroma A benign, well circumscribed adnexal neoplasm arising from the intraepidermal portion of the sweat gland duct. It usually presents as a solitary, dome-shaped papule, nodule, or plaque on acral sites. It is characterized by a proliferation of uniform basaloid cells in the dermis and is associated with the presence of focal ductal and cystic structures. Complete excision is curative. 8409/0 | morphology C176985 morphology C C177537 GDC Value Terminology C27534 Digital Papillary Adenocarcinoma An adenocarcinoma arising from the sweat glands. Most cases present as nodular lesions on the digits, usually in the hands. It is characterized by the presence of epithelial cells in the dermis forming nodules. Cystic structures containing papillary projections are also present. It may recur and metastasize, most commonly to the lungs. 8408/1 | morphology || 8408/3 | morphology || Aggressive digital papillary adenoma | primary_diagnosis || Digital papillary adenocarcinoma | primary_diagnosis || Eccrine papillary adenocarcinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C27753 Acute Myeloid Leukemia, Not Otherwise Specified Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme. 9861/3 | morphology || Acute myeloid leukemia, NOS | primary_diagnosis || Not Classified | fab_morphology_code C176985 || C177621 || C91220 morphology || primary_diagnosis || fab_morphology_code C C177537 GDC Value Terminology C28253 Milligram A metric unit of mass equal to one thousandth of a gram or 1000 micrograms. One milligram equals approximately 0.015 432 grain or 35.274 x 10E-6 ounce. mg | prescribed_dose_units || mg | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C28254 Milliliter A unit of volume equal to one millionth (10E-6) of a cubic meter, one thousandth of a liter, one cubic centimeter, or 0.061023 7 cubic inch. A cubic centimeter is the CGS unit of volume. mL | prescribed_dose_units || mL | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C2882 Arteriovenous Malformation A benign vascular lesion characterized by the presence of a complex network of communicating arterial and venous vascular structures. 9123/0 | morphology || Arteriovenous hemangioma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C2922 Skin Basosquamous Cell Carcinoma A basal cell carcinoma which displays squamous differentiation. The neoplastic cells have more abundant cytoplasm with more marked keratinization than typical basal cell carcinomas. It usually has a more aggressive clinical course compared to typical basal cell carcinoma, and it may produce regional or widespread metastases. 8094/3 | morphology || 8095/3 | morphology || Basosquamous carcinoma | primary_diagnosis || Metatypical carcinoma | primary_diagnosis || Mixed basal-squamous cell carcinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C2952 Ulcerative Colitis An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage. Ulcerative Colitis | comorbidities || Ulcerative Colitis | risk_factors C16457 || C17103 comorbidities || risk_factors C C177537 GDC Value Terminology C3117 Hypertension Blood pressure that is abnormally high. Hypertension | comorbidities || Hypertension | risk_factors C16457 || C17103 comorbidities || risk_factors C C177537 GDC Value Terminology C32298 Cervical Lymph Node Any of the lymph nodes located in the neck. Cervical lymph nodes | max_tumor_bulk_site || Cervical, NOS | lymph_node_involved_site || Lymph Node(s) Cervical | biospecimen_anatomic_site || Lymph Node(s) Cervical | treatment_anatomic_sites || Lymph Node, Cervical | sites_of_involvement C171435 || C173263 || C188396 || C33027 || C70729 biospecimen_anatomic_site || sites_of_involvement || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_sites C C177537 GDC Value Terminology C3276 Vestibular Schwannoma A benign peripheral nerve sheath neoplasm that arises from the vestibular division of the vestibulocochlear nerve (eight cranial nerve) in the auditory canal or within the labyrinth. It is composed almost entirely of differentiated neoplastic Schwann cells. 9560/0 | morphology || Acoustic neuroma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C33073 Mediastinal Lymph Node A lymph node located in the mediastinum. Mediastinal lymph nodes are arranged in three groups, one on the lateral, another on the medial, and a third on the anterior aspect of the vessels; the third group is, however, sometimes absent. Lymph Node(s) Mediastinal | treatment_anatomic_sites || Lymph Node, Mediastinal | sites_of_involvement || Lymph Nodes(s) Mediastinal | biospecimen_anatomic_site || Mediastinal | lymph_node_involved_site || Mediastinal lymph nodes | max_tumor_bulk_site C171435 || C173263 || C188396 || C33027 || C70729 biospecimen_anatomic_site || sites_of_involvement || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_sites C C177537 GDC Value Terminology C3709 Epithelial Neoplasm A benign, borderline, or malignant neoplasm that arises from and is composed of epithelial cells. Representative examples include adenomas and carcinomas. Epithelial Neoplasms, NOS | disease_type || Epithelioma, NOS | primary_diagnosis || Epithelioma, malignant | primary_diagnosis C177621 || C2991 primary_diagnosis || disease_type C C177537 GDC Value Terminology C3718 WAGR Syndrome A syndrome characterized by a predisposition for Wilms tumor, aniridia, genitourinary anomalies, and developmental delay. This is a contiguous gene syndrome due to deletion in the vicinity of chromosome 11p13 in a region containing the WT1 and PAX6 genes. Wagr Syndrome | comorbidities || Wagr Syndrome | risk_factors C16457 || C17103 comorbidities || risk_factors C C177537 GDC Value Terminology C3724 Cystic Hygroma A congenital lymphatic malformation that usually arises from the neck and is characterized by cystic dilation of the lymphatic vessels. 9173/0 | morphology || Cystic hygroma | primary_diagnosis || Cystic lymphangioma | primary_diagnosis || Hygroma, NOS | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C3770 Pancreatic Neuroendocrine Carcinoma An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas. The mitotic count is more than 20 per 10 HPF. It is classified as either small or large cell neuroendocrine carcinoma based on the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm. 8150/3 | morphology || Islet cell adenocarcinoma | primary_diagnosis || Islet cell carcinoma | primary_diagnosis || Pancreatic endocrine tumor, malignant | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C3774 Signet Ring Cell Adenocarcinoma A usually aggressive, poorly differentiated invasive adenocarcinoma characterized by the presence of malignant glandular cells in which the nucleus is pressed to one side by the presence of intracytoplasmic mucus. It may arise from the stomach, small and large intestine, ampulla of Vater, appendix, gallbladder, pancreas, lung, bladder, breast, and prostate gland. 8490/3 | morphology || Signet ring cell adenocarcinoma | primary_diagnosis || Signet ring cell carcinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C37967 Hypercholesterolemia A laboratory test result indicating an increased amount of cholesterol in the blood. Hypercholesterolemia | comorbidities || Hypercholesterolemia | risk_factors C16457 || C17103 comorbidities || risk_factors C C177537 GDC Value Terminology C38155 Recurrent Disease The return of a disease after a period of remission. Recurrence | first_event || Recurrence | timepoint_category || Recurrent Disease | initial_disease_status || Relapse | first_event C177616 || C198107 || C198201 initial_disease_status || first_event || timepoint_category C C177537 GDC Value Terminology C3819 Primary Amyloidosis Amyloidosis caused by monoclonal deposition of immunoglobulin light chain and, rarely, heavy chain fragments in organs and tissues. It is associated with plasma cell or B-cell lymphoproliferative disorders. 9769/1 | morphology || Primary amyloidosis | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C3879 Thyroid Gland Medullary Carcinoma A neuroendocrine carcinoma arising from the C-cells of the thyroid gland. It is closely associated with multiple endocrine neoplasia syndromes. Approximately 10% to 20% of medullary thyroid carcinomas are familial. Patients usually present with a thyroid nodule that is painless and firm. In the majority of cases nodal involvement is present at diagnosis. Surgery is the preferred treatment for both primary lesions and recurrences. This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy. 8345/3 | morphology || C cell carcinoma | primary_diagnosis || Parafollicular cell carcinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C40177 Uterine Corpus Smooth Muscle Tumor of Uncertain Malignant Potential A smooth muscle neoplasm that arises from the uterine corpus and cannot be reliably diagnosed as benign or malignant because of the presence of ambiguous morphologic findings. 8897/1 | morphology || Smooth muscle tumor of uncertain malignant potential | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C40203 Cervical Mucinous Adenocarcinoma, Intestinal-Type A cervical mucinous adenocarcinoma that resembles a large intestinal adenocarcinoma. Mucinous carcinoma, intestinal type | primary_diagnosis C177621 primary_diagnosis C C177537 GDC Value Terminology C4112 Trichofolliculoma A hair follicle lesion that presents as a solitary, colored, dome-shaped small papule. It consists of a central cystic follicular infundibulum from which numerous smaller hair follicles emanate into the surrounding dermis. The clinical course is benign. 8101/0 | morphology || Trichofolliculoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C4113 Trichilemmoma A benign neoplasm arising from the outer hair sheath and infundibulum. It occurs in the head and neck, usually on the face. It usually presents as an exophytic wart-like lesion or a dome-shaped lesion with a smooth surface. Morphologically, it is characterized by the proliferation of cuboidal cells with clear or eosinophilic cytoplasm in the dermis with connection to the epidermis/hair follicle. There is peripheral cellular palisading, and the lesion is surrounded by a hyaline band. 8102/0 | morphology || Trichilemmoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C41219 Native Hawaiian or Other Pacific Islander Individuals with origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands, including, for example, Native Hawaiian, Samoan, Chamorro, Tongan, Fijian, and Marshallese. native hawaiian or other pacific islander | race C17049 race C C177537 GDC Value Terminology C41259 American Indian or Alaska Native Individuals with origins in any of the original peoples of North, Central, and South America, including, for example, Navajo Nation, Blackfeet Tribe of the Blackfeet Indian Reservation of Montana, Native Village of Marrow Inupiat Traditional Government, Nome Eskimo Community, Aztec, and Maya. american indian or alaska native | race C17049 race C C177537 GDC Value Terminology C41260 Asian Individuals with origins in any of the original peoples of Central or East Asia, Southeast Asia, or South Asia including, for example, Chinese, Asian Indian, Filipino, Vietnamese, Korean, and Japanese. asian | race C17049 race C C177537 GDC Value Terminology C41261 White Individuals with origins in any of the original peoples of Europe, including for example, English, German, Irish, Italian, Polish, and Scottish. white | race C17049 race C C177537 GDC Value Terminology C4234 Giant Congenital Melanocytic Nevus A congenital melanocytic nevus that measures more than 200 mm or is unresectable. It usually presents as a dark brown to black hairy lesion. Morphologically, it is characterized by the presence of a compound or intradermal nevus. There is an increased risk of malignant transformation to melanoma, rhabdomyosarcoma, and poorly differentiated malignant tumors. 8761/1 | morphology || Giant pigmented nevus, NOS | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C4240 Melanoma Arising in Blue Nevus A rare melanoma which develops in a pre-existing blue nevus. It occurs more frequently on the scalp, face, orbit, back, buttocks, extremities, hands, and feet. 8780/3 | morphology || Blue nevus, malignant | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C42576 Kilogram per Cubic Meter A SI derived unit of mass concentration defined as the concentration of one kilogram of a substance per unit volume of the mixture equal to one cubic meter, or the concentration of one milligram of a substance per unit volume of the mixture equal to one milliliter, or one gram of a substance per one liter of the mixture. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one milliliter. g/L | test_units || mg/mL | prescribed_dose_units || mg/mL | treatment_dose_units C166199 || C206478 || C67415 treatment_dose_units || prescribed_dose_units || test_units C C177537 GDC Value Terminology C4299 Verrucous Venous Malformation A rare skin vascular malformation characterized by the proliferation of numerous dilated and congested capillaries and venules in the papillary dermis. It is associated with overlying epidermal acanthosis, hyperkeratosis, parakeratosis, and papillomatosis. It most often affects the distal extremities and manifests with red-to-purple plaques. 9142/0 | morphology || Verrucous keratotic hemangioma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C43234 Not Reported Not provided or available. Not Reported | adapter_content || Not Reported | adrenal_hormone || Not Reported | adverse_event || Not Reported | adverse_event_grade || Not Reported | ajcc_clinical_m || Not Reported | ajcc_clinical_n || Not Reported | ajcc_clinical_stage || Not Reported | ajcc_clinical_t || Not Reported | ajcc_pathologic_m || Not Reported | ajcc_pathologic_n || Not Reported | ajcc_pathologic_stage || Not Reported | ajcc_pathologic_t || Not Reported | ajcc_staging_system_edition || Not Reported | alcohol_frequency || Not Reported | alcohol_history || Not Reported | alcohol_intensity || Not Reported | alcohol_type || Not Reported | anaplasia_present || Not Reported | anaplasia_present_type || Not Reported | aneuploidy || Not Reported | ann_arbor_b_symptoms || Not Reported | ann_arbor_b_symptoms_described || Not Reported | ann_arbor_clinical_stage || Not Reported | ann_arbor_extranodal_involvement || Not Reported | ann_arbor_pathologic_stage || Not Reported | antigen || Not Reported | asbestos_exposure_type || Not Reported | barretts_esophagus_goblet_cells_present || Not Reported | basic_statistics || Not Reported | best_overall_response || Not Reported | biospecimen_anatomic_site || Not Reported | biospecimen_laterality || Not Reported | biospecimen_type || Not Reported | bone_marrow_malignant_cells || Not Reported | burkitt_lymphoma_clinical_variant || Not Reported | calgb_risk_group || Not Reported | cancer_detection_method || Not Reported | cause_of_death || Not Reported | cause_of_death_source || Not Reported | cdc_hiv_risk_factors || Not Reported | chemical_exposure_type || Not Reported | chemo_concurrent_to_radiation || Not Reported | child_pugh_classification || Not Reported | chromosomal_translocation || Not Reported | chromosome || Not Reported | chromosome_arm || Not Reported | clark_level || Not Reported | clinical_trial_indicator || Not Reported | clonality || Not Reported | cog_liver_stage || Not Reported | cog_neuroblastoma_risk_group || Not Reported | cog_renal_stage || Not Reported | cog_rhabdomyosarcoma_risk_group || Not Reported | columnar_mucosa_present || Not Reported | comorbidities || Not Reported | comorbidity_method_of_diagnosis || Not Reported | consistent_pathology_review || Not Reported | contiguous_organ_invaded || Not Reported | country_of_birth || Not Reported | country_of_residence_at_enrollment || Not Reported | diabetes_treatment_type || Not Reported | diagnosis_pathologically_confirmed || Not Reported | disease_response || Not Reported | disease_type || Not Reported | distance_normal_to_tumor || Not Reported | double_expressor_lymphoma || Not Reported | double_hit_lymphoma || Not Reported | drug_category || Not Reported | dysplasia_degree || Not Reported | dysplasia_type || Not Reported | ecog_performance_status || Not Reported | education_level || Not Reported | eln_risk_classification || Not Reported | embolic_agent || Not Reported | enneking_msts_grade || Not Reported | enneking_msts_metastasis || Not Reported | enneking_msts_stage || Not Reported | enneking_msts_tumor_site || Not Reported | ensat_clinical_m || Not Reported | ensat_pathologic_n || Not Reported | ensat_pathologic_stage || Not Reported | ensat_pathologic_t || Not Reported | environmental_tobacco_smoke_exposure || Not Reported | esophageal_columnar_dysplasia_degree || Not Reported | esophageal_columnar_metaplasia_present || Not Reported | evidence_of_progression_type || Not Reported | evidence_of_recurrence_type || Not Reported | exposure_duration || Not Reported | exposure_source || Not Reported | exposure_type || Not Reported | extracapsular_extension || Not Reported | extracapsular_extension_present || Not Reported | extranodal_extension || Not Reported | extrathyroid_extension || Not Reported | eye_color || Not Reported | figo_stage || Not Reported | first_event || Not Reported | first_symptom_prior_to_diagnosis || Not Reported | gastric_esophageal_junction_involvement || Not Reported | gene_symbol || Not Reported | gleason_grade_group || Not Reported | gleason_grade_tertiary || Not Reported | goblet_cells_columnar_mucosa_present || Not Reported | haart_treatment_indicator || Not Reported | hepatitis_sustained_virological_response || Not Reported | histologic_progression_type || Not Reported | histone_family || Not Reported | histone_variant || Not Reported | history_of_tumor || Not Reported | history_of_tumor_type || Not Reported | hormonal_contraceptive_type || Not Reported | hormonal_contraceptive_use || Not Reported | hormonal_replacement_therapy_status || Not Reported | hormone_replacement_therapy_type || Not Reported | hpv_strain || Not Reported | hysterectomy_margins_involved || Not Reported | hysterectomy_type || Not Reported | igcccg_stage || Not Reported | imaging_anatomic_site || Not Reported | imaging_findings || Not Reported | imaging_result || Not Reported | imaging_type || Not Reported | immunosuppressive_treatment_type || Not Reported | initial_disease_status || Not Reported | inpc_grade || Not Reported | inpc_histologic_group || Not Reported | inrg_stage || Not Reported | inss_stage || Not Reported | instrument_model || Not Reported | international_prognostic_index || Not Reported | irs_group || Not Reported | irs_stage || Not Reported | ishak_fibrosis_score || Not Reported | iss_stage || Not Reported | karnofsky_performance_status || Not Reported | kmer_content || Not Reported | laboratory_test || Not Reported | largest_extrapelvic_peritoneal_focus || Not Reported | laterality || Not Reported | lymph_node_dissection_site || Not Reported | lymph_node_involved_site || Not Reported | lymph_node_involvement || Not Reported | lymph_nodes_removed || Not Reported | lymphatic_invasion_present || Not Reported | margin_status || Not Reported | margins_involved_site || Not Reported | marital_status || Not Reported | masaoka_stage || Not Reported | measurement_type || Not Reported | measurement_unit || Not Reported | medulloblastoma_molecular_classification || Not Reported | melanoma_known_primary || Not Reported | menopause_status || Not Reported | metaplasia_present || Not Reported | metastasis_at_diagnosis || Not Reported | method_of_diagnosis || Not Reported | method_of_sample_procurement || Not Reported | micrometastasis_present || Not Reported | micropapillary_features || Not Reported | mismatch_repair_mutation || Not Reported | mitosis_karyorrhexis_index || Not Reported | molecular_analysis_method || Not Reported | molecular_consequence || Not Reported | morphologic_architectural_pattern || Not Reported | morphology || Not Reported | mutation_codon || Not Reported | necrosis_present || Not Reported | non_nodal_regional_disease || Not Reported | non_nodal_tumor_deposits || Not Reported | nononcologic_therapeutic_agents || Not Reported | normal_tumor_genotype_snp_match || Not Reported | number_of_pregnancies || Not Reported | occupation_type || Not Reported | ovarian_specimen_status || Not Reported | ovarian_surface_involvement || Not Reported | overrepresented_sequences || Not Reported | oxygen_use_indicator || Not Reported | oxygen_use_type || Not Reported | parent_with_radiation_exposure || Not Reported | pathogenicity || Not Reported | per_base_n_content || Not Reported | per_base_sequence_content || Not Reported | per_base_sequence_quality || Not Reported | per_sequence_gc_content || Not Reported | per_sequence_quality_score || Not Reported | per_tile_sequence_quality || Not Reported | perineural_invasion_present || Not Reported | peripancreatic_lymph_nodes_positive || Not Reported | peritoneal_fluid_cytological_status || Not Reported | peritoneal_washing_results || Not Reported | ploidy || Not Reported | prcc_type || Not Reported | pregnancy_outcome || Not Reported | pregnant_at_diagnosis || Not Reported | premature_at_birth || Not Reported | prescribed_dose_units || Not Reported | preservation_method || Not Reported | primary_diagnosis || Not Reported | primary_gleason_grade || Not Reported | primary_site || Not Reported | prior_treatment || Not Reported | procedures_performed || Not Reported | progression_or_recurrence || Not Reported | progression_or_recurrence_anatomic_site || Not Reported | progression_or_recurrence_type || Not Reported | radiosensitizing_agent || Not Reported | reason_treatment_ended || Not Reported | reason_treatment_not_given || Not Reported | reflux_treatment_type || Not Reported | relationship_primary_diagnosis || Not Reported | relationship_type || Not Reported | relative_deceased || Not Reported | relative_smoker || Not Reported | residual_disease || Not Reported | residual_tumor || Not Reported | residual_tumor_measurement || Not Reported | rhabdoid_present || Not Reported | risk_factor_method_of_diagnosis || Not Reported | risk_factor_treatment || Not Reported | risk_factors || Not Reported | route_of_administration || Not Reported | sarcomatoid_present || Not Reported | satellite_nodule_present || Not Reported | scan_tracer_used || Not Reported | second_gene_symbol || Not Reported | secondary_gleason_grade || Not Reported | secondhand_smoke_as_child || Not Reported | sequence_duplication_levels || Not Reported | sequence_length_distribution || Not Reported | site_of_resection_or_biopsy || Not Reported | sites_of_involvement || Not Reported | smoking_frequency || Not Reported | specimen_type || Not Reported | staining_intensity_scale || Not Reported | staining_intensity_value || Not Reported | supratentorial_localization || Not Reported | synchronous_malignancy || Not Reported | test_analyte_type || Not Reported | test_result || Not Reported | test_units || Not Reported | therapeutic_agents || Not Reported | therapeutic_levels_achieved || Not Reported | therapeutic_target_level || Not Reported | time_between_waking_and_first_smoke || Not Reported | timepoint_category || Not Reported | tissue_or_organ_of_origin || Not Reported | tissue_type || Not Reported | tobacco_smoking_status || Not Reported | transglottic_extension || Not Reported | treatment_anatomic_sites || Not Reported | treatment_dose_units || Not Reported | treatment_effect || Not Reported | treatment_effect_indicator || Not Reported | treatment_emergent_adverse_event || Not Reported | treatment_frequency || Not Reported | treatment_intent_type || Not Reported | treatment_outcome || Not Reported | treatment_type || Not Reported | tumor_confined_to_organ_of_origin || Not Reported | tumor_depth_descriptor || Not Reported | tumor_descriptor || Not Reported | tumor_focality || Not Reported | tumor_grade || Not Reported | tumor_grade_category || Not Reported | tumor_infiltrating_lymphocytes || Not Reported | tumor_infiltrating_macrophages || Not Reported | tumor_regression_grade || Not Reported | tumor_shape || Not Reported | type_of_smoke_exposure || Not Reported | uicc_clinical_m || Not Reported | uicc_clinical_n || Not Reported | uicc_clinical_stage || Not Reported | uicc_clinical_t || Not Reported | uicc_pathologic_m || Not Reported | uicc_pathologic_n || Not Reported | uicc_pathologic_stage || Not Reported | uicc_pathologic_t || Not Reported | uicc_staging_system_edition || Not Reported | ulceration_indicator || Not Reported | undescended_testis_corrected || Not Reported | undescended_testis_corrected_laterality || Not Reported | undescended_testis_corrected_method || Not Reported | undescended_testis_history || Not Reported | undescended_testis_history_laterality || Not Reported | variant_origin || Not Reported | variant_type || Not Reported | vascular_invasion_present || Not Reported | vascular_invasion_type || Not Reported | viral_hepatitis_serology_tests || Not Reported | vital_status || Not Reported | weiss_assessment_findings || Not Reported | weiss_assessment_score || Not Reported | who_cns_grade || Not Reported | who_nte_grade || Not Reported | wilms_tumor_histologic_subtype || Not Reported | zone_of_origin_prostate || Not Reported | zygosity || not reported | classification_of_tumor || not reported | ethnicity || not reported | gender || not reported | last_known_disease_status || not reported | prior_malignancy || not reported | progression_or_recurrence || not reported | race || not reported | relationship_gender || not reported | relative_with_cancer_history || not reported | treatment_or_therapy || not reported | vital_status C102562 || C102704 || C104014 || C104015 || C104017 || C104018 || C104023 || C104027 || C105721 || C106304 || C106317 || C106541 || C106551 || C111073 || C112400 || C121007 || C123560 || C125738 || C125904 || C126378 || C127762 || C127768 || C127772 || C129439 || C13202 || C133427 || C13355 || C133706 || C138899 || C139007 || C139577 || C140258 || C140259 || C140262 || C140266 || C141342 || C142346 || C143151 || C15256 || C154881 || C15599 || C156421 || C156422 || C157103 || C157110 || C157233 || C157410 || C157425 || C157437 || C158874 || C159229 || C159643 || C160720 || C160827 || C160837 || C160996 || C16124 || C161320 || C16165 || C162221 || C164057 || C16457 || C164683 || C16564 || C166199 || C166229 || C166276 || C16687 || C168796 || C17001 || C17049 || C17103 || C171253 || C17140 || C171435 || C173263 || C173544 || C17357 || C173595 || C17369 || C174459 || C175524 || C176287 || C176708 || C176985 || C177549 || C177550 || C177555 || C177556 || C177557 || C177558 || C177559 || C177561 || C177562 || C177564 || C177565 || C177566 || C177567 || C177568 || C177569 || C177570 || C177571 || C177572 || C177576 || C177577 || C177578 || C177579 || C177585 || C177586 || C177587 || C177588 || C177589 || C177590 || C177591 || C177592 || C177593 || C177594 || C177595 || C177596 || C177597 || C177598 || C177599 || C177600 || C177601 || C177602 || C177603 || C177604 || C177605 || C177606 || C177607 || C177608 || C177609 || C177610 || C177611 || C177612 || C177616 || C177617 || C177619 || C177620 || C177621 || C177622 || C177624 || C177626 || C177627 || C177628 || C177630 || C177631 || C177632 || C177633 || C177634 || C177635 || C177636 || C177637 || C177638 || C177640 || C177641 || C178243 || C178276 || C178286 || C178287 || C178288 || C178289 || C17953 || C181720 || C181723 || C182060 || C182097 || C182099 || C182101 || C182102 || C182109 || C182312 || C18304 || C185074 || C185264 || C185265 || C185266 || C185267 || C185268 || C185269 || C185270 || C185271 || C185272 || C185273 || C185274 || C185275 || C188000 || C188372 || C188373 || C188387 || C188388 || C188406 || C188408 || C188409 || C188411 || C188415 || C188429 || C188446 || C188448 || C188452 || C18849 || C18919 || C1909 || C19232 || C19697 || C19770 || C19796 || C198091 || C198092 || C198095 || C198101 || C198107 || C198127 || C198131 || C198139 || C198194 || C198195 || C198198 || C198200 || C198201 || C198204 || C198206 || C199145 || C200441 || C200442 || C200444 || C200446 || C200469 || C200473 || C200474 || C200476 || C200477 || C20118 || C202137 || C202138 || C202139 || C202140 || C202155 || C202157 || C202158 || C202159 || C202160 || C206478 || C206479 || C206480 || C2480 || C25185 || C25188 || C25193 || C25218 || C25294 || C25717 || C268 || C28013 || C28076 || C2873 || C29878 || C2991 || C33027 || C3420 || C35529 || C35886 || C36037 || C36292 || C38032 || C38114 || C39694 || C4086 || C41331 || C42578 || C43283 || C45824 || C45902 || C4809 || C48603 || C48604 || C48605 || C49236 || C50995 || C54398 || C574 || C67415 || C70700 || C70713 || C70729 || C81180 || C81229 || C81239 || C83280 || C83315 || C83393 || C85416 || C89081 || C90491 || C92808 || C93431 || C93711 || C94536 || C94811 || C95149 || C97229 || C97926 || C99532 inpc_grade || reason_treatment_not_given || weiss_assessment_score || weiss_assessment_findings || ensat_pathologic_stage || ensat_pathologic_t || ensat_pathologic_n || ensat_clinical_m || ecog_performance_status || tumor_regression_grade || mitosis_karyorrhexis_index || menopause_status || number_of_pregnancies || igcccg_stage || premature_at_birth || child_pugh_classification || margin_status || figo_stage || double_hit_lymphoma || alcohol_intensity || staining_intensity_value || perineural_invasion_present || vascular_invasion_present || medulloblastoma_molecular_classification || chromosome || inrg_stage || chromosome_arm || mismatch_repair_mutation || double_expressor_lymphoma || iss_stage || residual_tumor || enneking_msts_stage || enneking_msts_grade || enneking_msts_tumor_site || enneking_msts_metastasis || chemo_concurrent_to_radiation || gleason_grade_group || masaoka_stage || hysterectomy_type || ulceration_indicator || hormone_replacement_therapy_type || site_of_resection_or_biopsy || tissue_or_organ_of_origin || exposure_type || hpv_strain || first_symptom_prior_to_diagnosis || hormonal_contraceptive_use || tumor_focality || eye_color || primary_site || calgb_risk_group || lymph_nodes_removed || lymphatic_invasion_present || satellite_nodule_present || extranodal_extension || transglottic_extension || prior_treatment || synchronous_malignancy || haart_treatment_indicator || metastasis_at_diagnosis || type_of_smoke_exposure || comorbidities || treatment_emergent_adverse_event || ethnicity || treatment_dose_units || tumor_descriptor || reason_treatment_ended || histone_family || pathogenicity || ploidy || race || risk_factors || second_gene_symbol || environmental_tobacco_smoke_exposure || biospecimen_anatomic_site || sites_of_involvement || variant_type || gender || gene_symbol || imaging_type || classification_of_tumor || peritoneal_fluid_cytological_status || cause_of_death_source || imaging_result || morphology || irs_group || irs_stage || ajcc_clinical_stage || ajcc_pathologic_stage || test_analyte_type || ann_arbor_clinical_stage || ann_arbor_pathologic_stage || ajcc_staging_system_edition || eln_risk_classification || comorbidity_method_of_diagnosis || inpc_histologic_group || who_cns_grade || who_nte_grade || wilms_tumor_histologic_subtype || margins_involved_site || progression_or_recurrence_anatomic_site || supratentorial_localization || distance_normal_to_tumor || method_of_diagnosis || evidence_of_recurrence_type || dysplasia_degree || country_of_residence_at_enrollment || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || burkitt_lymphoma_clinical_variant || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || hysterectomy_margins_involved || metaplasia_present || necrosis_present || non_nodal_regional_disease || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || ovarian_surface_involvement || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || variant_origin || biospecimen_laterality || ajcc_clinical_m || ajcc_pathologic_m || ovarian_specimen_status || viral_hepatitis_serology_tests || instrument_model || ajcc_clinical_n || ajcc_pathologic_n || initial_disease_status || last_known_disease_status || pregnant_at_diagnosis || histone_variant || primary_diagnosis || relationship_gender || cdc_hiv_risk_factors || secondhand_smoke_as_child || smoking_frequency || time_between_waking_and_first_smoke || cog_liver_stage || cog_neuroblastoma_risk_group || cog_renal_stage || cog_rhabdomyosarcoma_risk_group || hepatitis_sustained_virological_response || ajcc_clinical_t || ajcc_pathologic_t || reflux_treatment_type || treatment_effect_indicator || progression_or_recurrence_type || esophageal_columnar_dysplasia_degree || relationship_primary_diagnosis || peripancreatic_lymph_nodes_positive || anaplasia_present || anaplasia_present_type || vascular_invasion_type || largest_extrapelvic_peritoneal_focus || education_level || consistent_pathology_review || undescended_testis_corrected_laterality || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || undescended_testis_corrected_method || undescended_testis_history_laterality || adrenal_hormone || imaging_anatomic_site || clonality || history_of_tumor_type || adapter_content || basic_statistics || kmer_content || overrepresented_sequences || per_base_n_content || per_base_sequence_content || per_base_sequence_quality || per_sequence_gc_content || per_sequence_quality_score || per_tile_sequence_quality || sequence_duplication_levels || sequence_length_distribution || alcohol_frequency || exposure_source || asbestos_exposure_type || clinical_trial_indicator || drug_category || uicc_clinical_m || uicc_clinical_n || uicc_clinical_stage || uicc_clinical_t || uicc_pathologic_m || uicc_pathologic_n || uicc_pathologic_stage || uicc_pathologic_t || zone_of_origin_prostate || history_of_tumor || prior_malignancy || treatment_outcome || therapeutic_agents || preservation_method || tissue_type || molecular_analysis_method || tobacco_smoking_status || cancer_detection_method || chemical_exposure_type || evidence_of_progression_type || extracapsular_extension || first_event || lymph_node_dissection_site || mutation_codon || peritoneal_washing_results || residual_tumor_measurement || risk_factor_method_of_diagnosis || therapeutic_levels_achieved || therapeutic_target_level || timepoint_category || tumor_grade_category || uicc_staging_system_edition || imaging_findings || country_of_birth || contiguous_organ_invaded || measurement_type || melanoma_known_primary || relative_smoker || tumor_depth_descriptor || tumor_shape || tumor_infiltrating_lymphocytes || tumor_infiltrating_macrophages || international_prognostic_index || extracapsular_extension_present || extrathyroid_extension || histologic_progression_type || micrometastasis_present || nononcologic_therapeutic_agents || oxygen_use_indicator || oxygen_use_type || radiosensitizing_agent || staining_intensity_scale || prescribed_dose_units || hormonal_replacement_therapy_status || prcc_type || scan_tracer_used || laterality || marital_status || occupation_type || treatment_type || laboratory_test || vital_status || antigen || karnofsky_performance_status || tumor_grade || aneuploidy || relative_with_cancer_history || disease_type || lymph_node_involved_site || chromosomal_translocation || lymph_node_involvement || morphologic_architectural_pattern || tumor_confined_to_organ_of_origin || test_result || treatment_effect || route_of_administration || sarcomatoid_present || dysplasia_type || adverse_event || measurement_unit || ann_arbor_b_symptoms_described || zygosity || alcohol_type || residual_disease || primary_gleason_grade || secondary_gleason_grade || gleason_grade_tertiary || treatment_or_therapy || disease_response || treatment_intent_type || immunosuppressive_treatment_type || test_units || method_of_sample_procurement || specimen_type || treatment_anatomic_sites || relative_deceased || alcohol_history || cause_of_death || exposure_duration || biospecimen_type || relationship_type || inss_stage || treatment_frequency || pregnancy_outcome || hormonal_contraceptive_type || procedures_performed || adverse_event_grade || best_overall_response || clark_level || ishak_fibrosis_score || embolic_agent || molecular_consequence || diabetes_treatment_type C C177537 GDC Value Terminology C43331 Fibrofolliculoma A rare hamartomatous papular lesion that arises from the hair follicle. It is characterized by the presence of a central dilated infundibulum from which epithelial strands and sebaceous glands emerge. The stroma is composed of collagen, spindle-shaped fibrocytes, and mucin. Patients with Birt-Hogg-Dube syndrome may develop multiple follicular fibromas. 8391/0 | morphology || Fibrofolliculoma | primary_diagnosis || Follicular fibroma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C43352 Turban Tumor Syndrome A rare autosomal dominant genodermatosis associated with germline mutations of the CYLD tumor suppressor gene. It is characterized by the development of multiple adnexal tumors (usually cylindromas and trichoepitheliomas), typically in the skin of the scalp. It manifests with numerous papules and/or large dome-shaped nodules on the scalp, resembling a turban. 8200/0 | morphology || Turban tumor | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C43356 Syringofibroadenoma A rare benign eccrine lesion usually arising on acral areas as a solitary papule or nodule. Multiple lesions are referred as syringofibroadenomatosis. It is characterized by the presence of epithelial cuboidal cells forming anastomosing cords in a fibrovascular stroma. 8392/0 | morphology || Syringofibroadenoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C4470 Perifollicular Fibroma A rare cutaneous hamartoma that arises from the connective tissue sheath of the hair follicle. It is characterized by the presence of fibroblasts surrounding the hair follicle. 8391/0 | morphology || Perifollicular fibroma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C4474 Benign Mixed Tumor of the Skin A rare, benign, slow-growing and painless neoplasm of sweat glands. It usually arises in the head and neck. It is characterized by the presence of a mesenchymal chondroid stroma, fibrosis, and epithelial structures. 8940/0 | morphology || Chondroid syringoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C4487 Tufted Hemangioma A rare cutaneous hemangioma characterized by the presence of multiple scattered and tightly packed lobules of capillaries in the dermis and rarely the subcutaneous tissue. It usually affects infants and children and manifests with macules, papules, nodules, or plaques. 9161/0 | morphology || Acquired tufted hemangioma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C45339 Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma An aggressive, epidermotropic primary cutaneous T-cell lymphoma composed of small to medium-sized, or medium-sized to large, CD8-positive T-lymphocytes with pleomorphic or blastic nuclei. Epidermotropism is often pronounced, and angiocentricity and angioinvasion may be present. It manifests with localized or disseminated eruptive papules and nodules or tumors. Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma | primary_diagnosis C177621 primary_diagnosis C C177537 GDC Value Terminology C45366 Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoproliferative Disorder A primary cutaneous T-cell lymphoproliferative disorder composed of small to medium-sized CD4-positive, CD8-negative, and CD30-negative pleomorphic T-lymphocytes in the dermis. A small number of large pleomorphic T-lymphocytes, focal epidermotropism, and subcutaneous involvement may be seen. It usually presents with a solitary plaque or tumor on the face, neck, or upper trunk. The clinical behavior is almost always indolent, and most patients present with localized disease. 9709/3 | morphology || Primary cutaneous CD4-positive small/medium T-cell lymphoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C4700 Giant Cell Fibroblastoma A morphologic variant of dermatofibrosarcoma protuberans that is most often seen in childhood and is characterized by the presence of spindle-shaped fibroblastic cells, a storiform growth pattern, numerous multinucleated giant cells, wide vessel-like spaces, and extensive myxoid change. 8834/1 | morphology || Giant cell fibroblastoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C4751 Pigmented Spindle Cell Nevus A subtype of Spitz nevus characterized by the presence of heavily pigmented spindle-shaped melanocytes that proliferate in the epidermis or in the epidermis and superficial dermis. It presents as a small and slightly elevated brown or black skin lesion with usually well-demarcated borders. Sometimes the clinical and morphologic features may be difficult to distinguish from melanoma. 8770/0 | morphology || Pigmented spindle cell nevus of Reed | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C4754 Spindle Cell Hemangioma A hemangioma characterized by the presence of spindle endothelial cells in the dermis with frequent extension in the subcutaneous tissue. It manifests with multiple asymptomatic bluish nodules and usually affects the distal extremities. 9136/1 | morphology || Spindle cell angioendothelioma | primary_diagnosis || Spindle cell hemangioendothelioma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C4810 Malignant Sweat Gland Neoplasm A malignant neoplasm that arises from the sweat glands. 8400/3 | morphology || Sweat gland tumor, malignant | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C48152 Microgram A metric unit of mass equal to one millionth of a gram or one thousandth of a milligram. ug | prescribed_dose_units || ug | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C48511 Millicurie A unit of radioactivity equal to one thousandth of a curie or 37 megabecquerels, and corresponding to a radioactivity of 37 millions of atomic disintegrations per second. mCi | prescribed_dose_units || mCi | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C48512 Milliequivalent A unit of relative amount of a substance equal to one thousandth of an equivalent weight. mEq | prescribed_dose_units || mEq | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C48552 Wafer Dosing Unit A dosing unit equal to the amount of active ingredient(s) contained in a wafer. Wafer | prescribed_dose_units || Wafer | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C48660 Not Applicable Determination of a value is not relevant in the current context. N/A | calgb_risk_group || Not Applicable | chipseq_antibody || Not Applicable | disease_type || Not Applicable | fragmentation_enzyme || Not Applicable | gene_symbol || Not Applicable | library_strand || Not Applicable | primary_site || Not Applicable | read_pair_number || Not Applicable | reflux_treatment_type || Not Applicable | target_capture_kit || Not Applicable | tumor_descriptor || Not Applicable | wgs_coverage C158874 || C159229 || C16515 || C166229 || C172300 || C173595 || C177563 || C177583 || C177613 || C177637 || C200470 || C2991 primary_site || calgb_risk_group || fragmentation_enzyme || tumor_descriptor || read_pair_number || gene_symbol || library_strand || target_capture_kit || chipseq_antibody || reflux_treatment_type || wgs_coverage || disease_type C C177537 GDC Value Terminology C49487 No The non-affirmative response to a question. No | adrenal_hormone || No | alcohol_history || No | anaplasia_present || No | ann_arbor_b_symptoms || No | ann_arbor_extranodal_involvement || No | barretts_esophagus_goblet_cells_present || No | bone_marrow_malignant_cells || No | chemo_concurrent_to_radiation || No | clinical_trial_indicator || No | columnar_mucosa_present || No | consistent_pathology_review || No | diagnosis_pathologically_confirmed || No | double_expressor_lymphoma || No | double_hit_lymphoma || No | environmental_tobacco_smoke_exposure || No | esophageal_columnar_metaplasia_present || No | extracapsular_extension_present || No | gastric_esophageal_junction_involvement || No | goblet_cells_columnar_mucosa_present || No | haart_treatment_indicator || No | hepatitis_sustained_virological_response || No | history_of_tumor || No | hormonal_replacement_therapy_status || No | lost_to_followup || No | lymph_nodes_removed || No | lymphatic_invasion_present || No | melanoma_known_primary || No | metaplasia_present || No | micrometastasis_present || No | mismatch_repair_mutation || No | necrosis_present || No | non_nodal_tumor_deposits || No | normal_tumor_genotype_snp_match || No | oxygen_use_indicator || No | parent_with_radiation_exposure || No | perineural_invasion_present || No | pregnant_at_diagnosis || No | premature_at_birth || No | prior_treatment || No | progression_or_recurrence || No | radiosensitizing_agent || No | relative_deceased || No | relative_smoker || No | rhabdoid_present || No | risk_factor_treatment || No | sarcomatoid_present || No | secondhand_smoke_as_child || No | synchronous_malignancy || No | therapeutic_levels_achieved || No | treatment_effect_indicator || No | tumor_confined_to_organ_of_origin || No | ulceration_indicator || No | undescended_testis_corrected || No | undescended_testis_history || No | vascular_invasion_present || no | prior_malignancy || no | progression_or_recurrence || no | relative_with_cancer_history || no | treatment_or_therapy C112400 || C125904 || C127768 || C127772 || C133706 || C138899 || C141342 || C154881 || C159643 || C159824 || C160720 || C16124 || C161320 || C16165 || C17140 || C177585 || C177586 || C177587 || C177589 || C177590 || C177591 || C177592 || C177593 || C177595 || C177596 || C177598 || C177599 || C177601 || C177602 || C177603 || C177619 || C177626 || C177634 || C177638 || C178286 || C181720 || C182060 || C182097 || C182099 || C182109 || C188387 || C18849 || C198198 || C200446 || C200469 || C202137 || C202140 || C202157 || C202159 || C206479 || C29878 || C36037 || C39694 || C49236 || C81180 || C81229 premature_at_birth || double_hit_lymphoma || perineural_invasion_present || vascular_invasion_present || mismatch_repair_mutation || double_expressor_lymphoma || chemo_concurrent_to_radiation || ulceration_indicator || lymph_nodes_removed || lost_to_followup || lymphatic_invasion_present || prior_treatment || synchronous_malignancy || haart_treatment_indicator || environmental_tobacco_smoke_exposure || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || metaplasia_present || necrosis_present || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || pregnant_at_diagnosis || secondhand_smoke_as_child || hepatitis_sustained_virological_response || treatment_effect_indicator || anaplasia_present || consistent_pathology_review || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || adrenal_hormone || clinical_trial_indicator || history_of_tumor || prior_malignancy || therapeutic_levels_achieved || melanoma_known_primary || relative_smoker || extracapsular_extension_present || micrometastasis_present || oxygen_use_indicator || radiosensitizing_agent || hormonal_replacement_therapy_status || relative_with_cancer_history || tumor_confined_to_organ_of_origin || sarcomatoid_present || treatment_or_therapy || relative_deceased || alcohol_history C C177537 GDC Value Terminology C49488 Yes The affirmative response to a question. Yes | adrenal_hormone || Yes | alcohol_history || Yes | anaplasia_present || Yes | ann_arbor_b_symptoms || Yes | ann_arbor_extranodal_involvement || Yes | barretts_esophagus_goblet_cells_present || Yes | bone_marrow_malignant_cells || Yes | chemo_concurrent_to_radiation || Yes | clinical_trial_indicator || Yes | columnar_mucosa_present || Yes | consistent_pathology_review || Yes | diagnosis_pathologically_confirmed || Yes | double_expressor_lymphoma || Yes | double_hit_lymphoma || Yes | environmental_tobacco_smoke_exposure || Yes | esophageal_columnar_metaplasia_present || Yes | extracapsular_extension_present || Yes | gastric_esophageal_junction_involvement || Yes | goblet_cells_columnar_mucosa_present || Yes | haart_treatment_indicator || Yes | hepatitis_sustained_virological_response || Yes | history_of_tumor || Yes | hormonal_replacement_therapy_status || Yes | lost_to_followup || Yes | lymph_nodes_removed || Yes | lymphatic_invasion_present || Yes | melanoma_known_primary || Yes | metaplasia_present || Yes | micrometastasis_present || Yes | mismatch_repair_mutation || Yes | necrosis_present || Yes | non_nodal_tumor_deposits || Yes | normal_tumor_genotype_snp_match || Yes | oxygen_use_indicator || Yes | parent_with_radiation_exposure || Yes | perineural_invasion_present || Yes | pregnant_at_diagnosis || Yes | premature_at_birth || Yes | prior_treatment || Yes | progression_or_recurrence || Yes | radiosensitizing_agent || Yes | relative_deceased || Yes | relative_smoker || Yes | rhabdoid_present || Yes | risk_factor_treatment || Yes | sarcomatoid_present || Yes | secondhand_smoke_as_child || Yes | synchronous_malignancy || Yes | therapeutic_levels_achieved || Yes | treatment_effect_indicator || Yes | tumor_confined_to_organ_of_origin || Yes | ulceration_indicator || Yes | undescended_testis_corrected || Yes | undescended_testis_history || Yes | vascular_invasion_present || yes | prior_malignancy || yes | progression_or_recurrence || yes | relative_with_cancer_history || yes | treatment_or_therapy C112400 || C125904 || C127768 || C127772 || C133706 || C138899 || C141342 || C154881 || C159643 || C159824 || C160720 || C16124 || C161320 || C16165 || C17140 || C177585 || C177586 || C177587 || C177589 || C177590 || C177591 || C177592 || C177593 || C177595 || C177596 || C177598 || C177599 || C177601 || C177602 || C177603 || C177619 || C177626 || C177634 || C177638 || C178286 || C181720 || C182060 || C182097 || C182099 || C182109 || C188387 || C18849 || C198198 || C200446 || C200469 || C202137 || C202140 || C202157 || C202159 || C206479 || C29878 || C36037 || C39694 || C49236 || C81180 || C81229 premature_at_birth || double_hit_lymphoma || perineural_invasion_present || vascular_invasion_present || mismatch_repair_mutation || double_expressor_lymphoma || chemo_concurrent_to_radiation || ulceration_indicator || lymph_nodes_removed || lost_to_followup || lymphatic_invasion_present || prior_treatment || synchronous_malignancy || haart_treatment_indicator || environmental_tobacco_smoke_exposure || ann_arbor_b_symptoms || ann_arbor_extranodal_involvement || bone_marrow_malignant_cells || columnar_mucosa_present || diagnosis_pathologically_confirmed || esophageal_columnar_metaplasia_present || gastric_esophageal_junction_involvement || barretts_esophagus_goblet_cells_present || goblet_cells_columnar_mucosa_present || metaplasia_present || necrosis_present || non_nodal_tumor_deposits || normal_tumor_genotype_snp_match || progression_or_recurrence || rhabdoid_present || risk_factor_treatment || pregnant_at_diagnosis || secondhand_smoke_as_child || hepatitis_sustained_virological_response || treatment_effect_indicator || anaplasia_present || consistent_pathology_review || parent_with_radiation_exposure || undescended_testis_corrected || undescended_testis_history || adrenal_hormone || clinical_trial_indicator || history_of_tumor || prior_malignancy || therapeutic_levels_achieved || melanoma_known_primary || relative_smoker || extracapsular_extension_present || micrometastasis_present || oxygen_use_indicator || radiosensitizing_agent || hormonal_replacement_therapy_status || relative_with_cancer_history || tumor_confined_to_organ_of_origin || sarcomatoid_present || treatment_or_therapy || relative_deceased || alcohol_history C C177537 GDC Value Terminology C5117 Carcinoma Arising from Spiradenoma A very rare, aggressive carcinoma of the sweat glands arising from malignant transformation of a long standing spiradenoma. It usually grows in the upper extremities, lower extremities, trunk, and head and neck. It has the tendency to recur and metastasize most often to the lymph nodes, bones, and lungs. 8403/3 | morphology || Malignant eccrine spiradenoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C53595 Branchioma A rare, benign, well-circumscribed or encapsulated tumor that arises from the neck and occurs in adults. It is characterized by the presence of spindle cells, epithelial islands, and adipose tissue. 8587/0 | morphology || Ectopic hamartomatous thymoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C64693 Centigray The metric unit of absorbed radiation dose equal to the absorption of one hundredth of joule of radiation energy per kilogram of matter. cGy | prescribed_dose_units || cGy | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C64774 Area Under Curve The area between the x-axis and the curve given by the integrand. It is equal to the definite integral of a function. In the field of pharmacokinetics, the area under the curve (AUC) is the area under the curve in a plot of concentration of a drug in plasma against time. AUC is usually given for the time interval zero to infinity, and other time intervals are indicated. AUC | prescribed_dose_units || AUC | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C64850 Hepatitis B Virus Surface Antigen Measurement A determination of the presence of hepatitis B virus surface antigen. Hepatitis B Surface Antigen | viral_hepatitis_serology_tests C177609 viral_hepatitis_serology_tests C C177537 GDC Value Terminology C6645 Infantile Hemangioma A hemangioma that is characterized by the proliferation of lobules of capillaries. It occurs in infants and children and may regress spontaneously. 9131/0 | morphology || Hemangioma simplex | primary_diagnosis || Infantile hemangioma | primary_diagnosis || Juvenile hemangioma | primary_diagnosis || Plexiform hemangioma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C66717 Metastatic Signet Ring Cell Adenocarcinoma A signet ring cell carcinoma that has spread from its original site of growth to another anatomic site. 8490/6 | morphology || Metastatic signet ring cell carcinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C66753 Melanoma in Precancerous Melanosis A melanoma arising from an atypical intraepithelial melanocytic hyperplasia. 8741/3 | morphology || Malignant melanoma in precancerous melanosis | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C66754 Small Congenital Melanocytic Nevus A congenital melanocytic nevus of small size, with a diameter smaller than 15 mm. It presents as a macular, papular or plaque-like lesion. 8761/0 | morphology || Small congenital nevus | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C66757 Epithelioid Cell Nevus A Spitz nevus characterized by the presence of large epithelioid melanocytes. 8771/0 | morphology || Epithelioid cell nevus | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C66974 Milligram per Square Meter per Day A dose calculation unit expressed in milligram(s) per square meter per period of time equal to twenty-four hours. mg/m2/day | prescribed_dose_units || mg/m2/day | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C66976 Milligram per Kilogram per Day A dose calculation unit expressed in milligram(s) per kilogram per period of time equal to twenty-four hours. mg/kg/day | prescribed_dose_units || mg/kg/day | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C67015 Milligram per Deciliter A unit of mass concentration defined as the concentration of one milligram of a substance in unit volume of the mixture equal to one cubic deciliter or 100 cubic centimeters. It is also a unit of mass density (volumic mass) defined as the density of substance which mass equal to one milligram occupies the volume one cubic deciliter or 100 cubic centimeters. mg/dL | prescribed_dose_units || mg/dL | test_units || mg/dL | treatment_dose_units C166199 || C206478 || C67415 treatment_dose_units || prescribed_dose_units || test_units C C177537 GDC Value Terminology C67282 Gram per Square Meter A metric unit of areal density defined as a spread rate at which one gram of a substance is spread over the area of one square meter. It is equal to approximately 0.029 4935 ounce per square yard. Also used as a dose calculation unit to express quantity of an agent in grams per body surface area in square meters. g/m2 | prescribed_dose_units || g/m2 | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C67312 Microgram per Square Meter A metric unit of areal density equal to approximately 2.94935E-8 ounce per square yard. Also used as a dose calculation unit. ug/m2 | prescribed_dose_units || ug/m2 | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C67316 Milliinternational Unit A unit equal to one-thousandth of an international unit. mIU | prescribed_dose_units || mIU | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C67372 Gram per 24 Hours A metric mass flow rate unit equal to the rate at which mass of matter of one gram crosses a given surface or/and is transferred over a period of twenty four hours. g/day | prescribed_dose_units || g/day | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C67379 International Unit per Kilogram A unit of measure of a quantity of substance per unit mass, expressed as the quantity of substance in International Units, divided by the mass of the substance in kilograms. It is also used as a dose calculation unit expressed in International Units of biological activity per one kilogram of body mass. IU/kg | prescribed_dose_units || IU/kg | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C67380 International Unit per Milligram A unit of measure of quantity of substance per unit mass, expressed in terms of International Units per milligram. (CDISC) IU/mg | prescribed_dose_units || IU/mg | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C67399 Milligram per 24 Hours A unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to twenty four hours. Milligram per twenty four hours is also a dose administration rate unit equal to the rate at which one thousandth of a gram of a product is administered per unit of time equal to twenty four hours. mg/24 hr | test_units || mg/day | prescribed_dose_units || mg/day | treatment_dose_units C166199 || C206478 || C67415 treatment_dose_units || prescribed_dose_units || test_units C C177537 GDC Value Terminology C67401 Milligram per Kilogram A unit of a mass fraction expressed as a number of milligrams of substance per kilogram of mixture. The unit is also used as a dose calculation unit. mg/kg | prescribed_dose_units || mg/kg | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C67402 Milligram per Square Meter A metric unit of areal density equal to approximately 2.94935E-5 ounce per square yard. Also used as a dose calculation unit. mg/m2 | prescribed_dose_units || mg/m2 | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C67404 Milligram per Week A dose administration rate unit equal to the rate at which one thousandth of a gram of a product is delivered or administered over the time period of one week. This is also a unit of mass flow rate equivalent to the rate at which one thousandth of a gram of matter crosses a given surface or is delivered to a given object or space over a period of time equal to one week. mg/wk | prescribed_dose_units || mg/wk | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C6879 Pancreatic Mixed Ductal Adenocarcinoma-Neuroendocrine Carcinoma A carcinoma that arises from the pancreas and is composed of ductal adenocarcinoma and neuroendocrine carcinoma components in both the primary tumor and the metastatic sites. Mixed ductal-endocrine carcinoma | primary_diagnosis C177621 primary_diagnosis C C177537 GDC Value Terminology C6891 Meningeal Melanomatosis A rare condition in patients with leptomeningeal melanoma characterized by diffuse or multifocal proliferation of melanoma cells in the leptomeninges. It is often associated with invasion of the central nervous system. 8728/3 | morphology || Meningeal melanomatosis | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C6938 Sweat Gland Carcinoma A carcinoma that arises from the sweat glands. Representative examples include porocarcinoma, hidradenocarcinoma, microcystic adnexal carcinoma, skin adenoid cystic carcinoma, apocrine carcinoma, and digital papillary adenocarcinoma. 8400/3 | morphology || Sweat gland adenocarcinoma | primary_diagnosis || Sweat gland carcinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C70430 Zero A mathematical element that when added to another number yields the same number; the cardinal number meaning one less than one. 0 | peripancreatic_lymph_nodes_positive || 0 | weiss_assessment_score C104014 || C178276 weiss_assessment_score || peripancreatic_lymph_nodes_positive C C177537 GDC Value Terminology C7137 Cutaneous Mastocytosis Mastocytosis characterized by infiltration of the skin by mast cells. 9740/1 | morphology || Cutaneous mastocytosis | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C72074 Neuroendocrine Tumor G2 A well-differentiated, intermediate-grade epithelial neoplasm with neuroendocrine differentiation. It usually arises from the digestive system, lung, and head and neck. 8249/3 | morphology || Atypical carcinoid tumor | primary_diagnosis || G2 | who_nte_grade C176985 || C177567 || C177621 morphology || who_nte_grade || primary_diagnosis C C177537 GDC Value Terminology C7401 Hairy Cell Leukemia Variant An indolent chronic B-cell leukemia resembling classic hairy cell leukemia but shows variant cytologic, hematologic, and immunophenotypic features and is resistant to the conventional therapy applied to hairy cell leukemia. Biologically, it is not related to hairy cell leukemia. 9591/3 | morphology || 9940/3 | morphology || Hairy cell leukemia variant | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C74711 Hepatitis B Surface Antibody Measurement The determination of the surface antibody reaction of a sample to the Hepatitis B virus. HBV Surface Antibody | viral_hepatitis_serology_tests C177609 viral_hepatitis_serology_tests C C177537 GDC Value Terminology C7526 Papillary Intralymphatic Angioendothelioma A rare, intermediate and rarely metastasizing blood vessel neoplasm that most often affects the skin and soft tissue of the extremities and manifests as a slow-growing induration, nodule, or plaque. Rare cases have been described in the spleen, tongue, and testis as well. It is characterized by the presence of lymphatic-like vascular channels and papillary endothelial proliferation. 9135/1 | morphology || Dabska tumor | primary_diagnosis || Endovascular papillary angioendothelioma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C7563 Hidradenoma A benign epithelial neoplasm arising from the sweat glands. Variants include the clear cell, nodular, and solid cystic hidradenoma. 8400/0 | morphology || 8402/0 | morphology || Eccrine acrospiroma | primary_diagnosis || Hidradenoma, NOS | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C7567 Clear Cell Hidradenoma A hidradenoma with apocrine differentiation. It is characterized by the presence of cells with vesicular nuclei and eosinophilic cytoplasm and cells with clear cytoplasm and often eccentrically located nuclei. 8402/0 | morphology || Clear cell hidradenoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C7568 Nodular Hidradenoma A hidradenoma characterized by a nodular growth pattern. It presents as a nodular lesion usually in the scalp, trunk, and proximal extremities. Complete excision is curative. 8402/0 | morphology || Nodular hidradenoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C770 Prednisone A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations. Prednisone | immunosuppressive_treatment_type || Prednisone | therapeutic_agents C1909 || C574 therapeutic_agents || immunosuppressive_treatment_type C C177537 GDC Value Terminology C77641 Mesenteric Lymph Node A lymph node located in the mesentery. Lymph Node(s) Mesenteric | biospecimen_anatomic_site || Lymph Node(s) Mesenteric | treatment_anatomic_sites || Lymph Node, Mesenteric | sites_of_involvement || Mesenteric | lymph_node_involved_site || Mesenteric lymph nodes | max_tumor_bulk_site C171435 || C173263 || C188396 || C33027 || C70729 biospecimen_anatomic_site || sites_of_involvement || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_sites C C177537 GDC Value Terminology C77643 Paraaortic Lymph Node A lymph node located adjacent to the lumbar region of the spine. Aortic | lymph_node_involved_site || Lymph Node(s) Paraaortic | biospecimen_anatomic_site || Lymph Node(s) Paraaortic | treatment_anatomic_sites || Lymph Node, Para-Aortic | sites_of_involvement || Paraaortic | lymph_node_involved_site || Paraaortic lymph nodes | max_tumor_bulk_site C171435 || C173263 || C188396 || C33027 || C70729 biospecimen_anatomic_site || sites_of_involvement || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_sites C C177537 GDC Value Terminology C77650 Submandibular Lymph Node A lymph node located beneath the floor of the oral cavity. Lymph Node(s) Submandibular | biospecimen_anatomic_site || Lymph Node(s) Submandibular | treatment_anatomic_sites || Lymph Node, Submandibular | sites_of_involvement || Submandibular | lymph_node_involved_site || Submandibular lymph nodes | max_tumor_bulk_site C171435 || C173263 || C188396 || C33027 || C70729 biospecimen_anatomic_site || sites_of_involvement || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_sites C C177537 GDC Value Terminology C77971 Immunotherapy Regimen MKC-1106-MT A regimen containing three components: a plasmid encoding portions of the two melanoma-associated antigens Melan A (also called MART-1) and tyrosinase and two synthetic analogs of Melan-A and tyrosinase antigen epitopes with potential immunostimulating and antitumor activities. First, the plasmid is injected directly into lymph nodes in order to sensitize or prime antigen-presenting cells (APCs) and central memory T cells in lymph nodes to plasmid-expressed Melan A and tyrosinase. After several priming injections with plasmids, the Melan A and tyrosinase synthetic epitope analogs are injected directly into lymph nodes; upon binding to major histocompatibility complex (MHC) molecules on APC cell surfaces, these synthetic epitope analogs may stimulate a "primed" cytotoxic T lymphocyte (CTL) response against melanoma tumor cells, resulting in tumor cell lysis. Melan-A and tyrosinase are overexpressed by melanoma tumor cells. Immunotherapy Regimen MKC-1106-MT | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C78204 Regorafenib Anhydrous The anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling. Regorafenib | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C7927 Liver Carcinoma A carcinoma that arises from the hepatocytes or intrahepatic bile ducts. The main subtypes are hepatocellular carcinoma (hepatoma) and cholangiocarcinoma. Liver Cancer | relationship_primary_diagnosis C178243 relationship_primary_diagnosis C C177537 GDC Value Terminology C81767 Indeterminate Dendritic Cell Tumor A very rare dendritic cell tumor composed of spindle to ovoid cells with a phenotype that is similar to the Langerhans cells. Patients usually present with cutaneous papules, nodules, and plaques. Systemic symptoms are usually absent. The clinical course is variable. 9757/3 | morphology || Indeterminate dendritic cell tumor | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C82383 Nirogacestat A selective gamma secretase (GS) inhibitor with antitumor activity. Upon administration, nirogacestat targets and binds to GS, thereby blocking the proteolytic activation of Notch receptors. This inhibits the Notch signaling pathway and results in the induction of apoptosis in tumor cells that overexpress Notch. The integral membrane protein GS is a multi-subunit protease complex that cleaves single-pass transmembrane proteins, such as Notch receptors, at residues within their transmembrane domains. Overexpression of the Notch signaling pathway has been correlated with increased tumor cell growth and survival. Nirogacestat | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C82676 Irinotecan Sucrosofate A liposomal dispersion formulated with the semisynthetic camptothecin analogue irinotecan, provided as the hydrochloride trihydrate form, which is encapsulated and entrapped within liposomes in a gelated or precipitated state as the irinotecan sucrose octasulfate (sucrosulfate) salt form, with potential antineoplastic activity. Upon administration of the liposomes containing irinotecan sucrosulfate, irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. During the S-phase, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Liposome encapsulation of this agent promotes efficient drug delivery into the cytosol from the endosome compartment of the cell, extends the circulation of irinotecan, and prolongs the duration of active therapy at the site of tumor to inhibit tumor growth. Irinotecan Sucrosofate | therapeutic_agents || Liposomal Irinotecan | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C86071 Equivocal Open to question. Equivocal | anaplasia_present_type || Equivocal | imaging_findings || Equivocal | test_result C178287 || C199145 || C36292 anaplasia_present_type || imaging_findings || test_result C C177537 GDC Value Terminology C88143 External Iliac Lymph Node A lymph node located along the external iliac artery. Iliac-external | lymph_node_involved_site || Iliac-external | max_tumor_bulk_site || Lymph Node(s) Iliac-External | biospecimen_anatomic_site || Lymph Node(s) Iliac-External | treatment_anatomic_sites || Lymph Node, Iliac-External | sites_of_involvement C171435 || C173263 || C188396 || C33027 || C70729 biospecimen_anatomic_site || sites_of_involvement || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_sites C C177537 GDC Value Terminology C88148 Milligram per Square Meter per Week A dose calculation unit expressed in milligram(s) per square meter per period of time equal to seven days. mg/m2/wk | prescribed_dose_units || mg/m2/wk | treatment_dose_units C166199 || C206478 treatment_dose_units || prescribed_dose_units C C177537 GDC Value Terminology C9128 Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive A chronic myeloid leukemia characterized by the t(9;22)(q34;q11) chromosomal translocation, resulting in the presence of the Philadelphia chromosome and the BCR-ABL1 fusion gene. 9875/3 | morphology || Chronic granulocytic leukemia, BCR/ABL | primary_diagnosis || Chronic granulocytic leukemia, Philadelphia chromosome (Ph1) positive | primary_diagnosis || Chronic granulocytic leukemia, t(9;22)(q34;q11) | primary_diagnosis || Chronic myelogenous leukemia, Philadelphia chromosome (Ph 1) positive | primary_diagnosis || Chronic myelogenous leukemia, t(9;22)(q34;q11) | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C9231 Merkel Cell Carcinoma A rare aggressive neuroendocrine carcinoma that usually arises from the skin. Rarely, it arises from extracutaneous sites, including the oral cavity, salivary glands, breast, vulva, and vaginal wall. The tumor is composed of small round cells with scanty cytoplasm. Merkel cell polyomavirus is implicated in the majority of cases. 8247/3 | morphology || Merkel cell carcinoma | primary_diagnosis || Merkel cell tumor | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C92535 Hepatitis C Antibody Measurement A quantitative measurement of the antibody reaction of a biological specimen to the Hepatitis C virus. Hepatitis C Antibody | viral_hepatitis_serology_tests C177609 viral_hepatitis_serology_tests C C177537 GDC Value Terminology C9498 Melanocytoma A usually benign neoplasm that arises from the sun-exposed skin, eye, and meninges. It is composed of spindle and/or epithelioid melanocytes and melanophages. It rarely progresses to melanoma. 8726/0 | morphology || Magnocellular nevus | primary_diagnosis || Melanocytoma, NOS | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis C C177537 GDC Value Terminology C95769 Genistein Sodium Dihydrate The sodium salt dihydrate form of crystalline genistein, a soy-derived isoflavone and phytoestrogen, with potential antineoplastic, chemosensitizing, and antioxidant activities. Upon administration, genistein sodium dihydrate binds to and modulates the activities of the nuclear estrogen receptors ERalpha (ESR1) and ERbeta (ESR2), and activates the G-coupled estrogen receptor 1 (GPER1). In addition, this agent increases the expression of phosphatase and tensin homolog (PTEN), which deactivates protein kinase Akt and mitogen-activated protein kinases (MAPK1 and 3; ERK2 and 1), thereby disrupting PI3K/Akt signal transduction and inducing apoptosis. Genistein sodium dihydrate also induces antioxidant enzymes through AMP-activated protein kinase (AMPK) activation, inhibits nuclear factor kappa-B (NF-kB) activation and decreases inflammation response, thereby sensitizing tumors to chemotherapy. Compared to genistein itself, which has poor oral availability, this crystalline formulation shows improved solubility and bioavailability. Crystalline Genistein Formulation AXP107-11 | therapeutic_agents C1909 therapeutic_agents C C177537 GDC Value Terminology C96258 FIGO Stage IIIC A FIGO stage term that applies to gynecologic cancers. For endometrial cancer, it refers to cancer with metastasis to the pelvic or para-aortic lymph nodes or both. Stage IIIC | figo_stage C125738 figo_stage C C177537 GDC Value Terminology C96259 FIGO Stage IIIC1 A FIGO stage term that applies to gynecologic cancers. For endometrial cancer, it refers to cancer with regional metastasis to pelvic lymph nodes. Stage IIIC1 | figo_stage C125738 figo_stage C C177537 GDC Value Terminology C96260 FIGO Stage IIIC2 A FIGO stage term that applies to gynecologic cancers. For endometrial cancer, it refers to it refers to cancer with regional metastasis to para-aortic lymph nodes with or without metastasis to pelvic lymph nodes. Stage IIIC2 | figo_stage C125738 figo_stage C C177537 GDC Value Terminology C96660 Hepatitis B Virus Core Antibody Measurement The determination of the amount of Hepatitis B virus core antibody present in a sample. HBV Core Antibody | viral_hepatitis_serology_tests C177609 viral_hepatitis_serology_tests C C177537 GDC Value Terminology C98183 Femoral Lymph Node A lymph node located in the upper inner portion of the thigh. Femoral | lymph_node_involved_site || Femoral | lymph_node_involved_site || Lymph Node(s) Femoral | biospecimen_anatomic_site || Lymph Node(s) Femoral | treatment_anatomic_sites || Lymph Node, Femoral | sites_of_involvement C171435 || C173263 || C33027 || C70729 biospecimen_anatomic_site || sites_of_involvement || lymph_node_involved_site || treatment_anatomic_sites C C177537 GDC Value Terminology C98189 Retroperitoneal Lymph Node A lymph node located in the retroperitoneal space. Lymph Node(s) Retroperitoneal | biospecimen_anatomic_site || Lymph Node(s) Retroperitoneal | treatment_anatomic_sites || Lymph Node, Retroperitoneal | sites_of_involvement || Retroperitoneal | lymph_node_involved_site || Retroperitoneal lymph nodes | max_tumor_bulk_site C171435 || C173263 || C188396 || C33027 || C70729 biospecimen_anatomic_site || sites_of_involvement || max_tumor_bulk_site || lymph_node_involved_site || treatment_anatomic_sites D C177537 GDC Value Terminology C107679 Liposomal Rhenium Re 186 A therapeutic preparation consisting of the beta-emitting radioisotope rhenium Re 186 encapsulated in a nanoliposome, with potential antineoplastic activity. Upon intratumoral infusion of liposomal rhenium Re 186, the radioisotope releases radiation, which directly kills the tumor cells. The nanoliposomes facilitate the retention of the radioisotope by the tumor cells and localize the radiocytotoxicity to the tumor while sparing surrounding normal, healthy cells. Re-186 has a short half-life and a short path length, which contributes further to limiting the radiotoxicity to the tumor cells. Liposomal Rhenium Re 186 | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C128560 Cord Blood-derived Expanded Natural Killer Cells PNK-007 A population of allogeneic lytic natural killer (NK) cells derived from human umbilical cord blood (UCB), with potential cytotoxic activity. Hematopoietic stem cells (HSC) are isolated from human UCB; this is followed by ex vivo differentiation into mature, highly lytic, NK cells, and expansion. Upon administration, the CB-derived expanded NK cells PNK-007 may lyse cancer cells. Cord Blood-derived Expanded Natural Killer Cells PNK-007 | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C143155 Trimeric GITRL-Fc OMP-336B11 A Fc-engineered human fusion protein composed of two trimers of tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18; GlTRL) linked to an immunoglobulin Fc domain (GITRL-Fc), with potential immunostimulatory and antineoplastic activities. Upon administration, trimeric GITRL-Fc OMP-336B11 targets, binds to and activates its co-stimulatory surface receptor (glucocorticoid-induced tumor necrosis factor receptor (GITR; TNFRSF18) expressed on T-lymphocytes and certain tumor cell types. This activates T-lymphocytes, causes T-lymphocyte proliferation and suppresses the activity of regulatory T-cells (Treg). This promotes cytotoxic T-lymphocyte (CTL)-mediated killing of tumor cells. GITRL, a member of the tumor necrosis factor (TNF) family of ligands, functions to activate the co-stimulatory receptor GITR to enhance T-cell modulated immune responses. Trimeric GITRL-Fc OMP-336B11 | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C156052 BCMA x CD3 T-cell Engaging Antibody CC-93269 A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17), and one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration of anti-BCMA/CD3 T-cell engaging antibody CC-93269, this bispecific antibody binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA found on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival. BCMA x CD3 T-cell Engaging Antibody CC-93269 | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C162848 Digital Papillary Adenoma An eccrine sweat gland adenoma with aggressive local growth. Most cases present as nodular lesions on the digits. It is characterized by the presence of tubular and ductal structures with areas of papillary projections into cystic lumina. 8408/1 | morphology || Aggressive digital papillary adenoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C172809 Tyrosine Kinase Inhibitor TL-895 An orally bioavailable inhibitor of tyrosine kinase, with potential anti-inflammatory and antineoplastic activities. Upon oral administration, tyrosine kinase inhibitor TL-895 targets, binds to, and inhibits tyrosine kinase. This may result in the inhibition of tumor angiogenesis and cell proliferation, and the inhibition of immune-mediated inflammatory processes. Tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis. In addition, they play important roles in the activation of leukocytes and in many immune-mediated inflammatory and autoimmune conditions. Tyrosine Kinase Inhibitor TL-895 | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C173536 Bcl-2 Inhibitor LP-108 An orally bioavailable inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon oral administration, Bcl-2 inhibitor LP-108 targets, binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. Bcl-2 is overexpressed in many cancers and plays an important role in the negative regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Bcl-2 Inhibitor LP-108 | therapeutic_agents C1909 therapeutic_agents D C177537 GDC Value Terminology C184800 Somatic Variation Rate The frequency of mutations in a sample derived from non-germline cells or tissues. Somatic Mutation Index | data_type C172272 data_type D C177537 GDC Value Terminology C27254 Papillary Eccrine Carcinoma A carcinoma of the eccrine glands. It consists of dilated ducts with papillary projections. 8408/3 | morphology || Eccrine papillary adenocarcinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C2874 Angiokeratoma A vascular lesion in the papillary dermis resulting from ectasia of pre-existing vessels. It is associated with secondary proliferative changes in the overlying epidermis (hyperkeratosis). It can present with widespread lesions (angiokeratoma corporis diffusum, often associated with inborn errors of metabolism) or as a localized lesion (angiokeratoma of Fordyce, angiokeratoma circumscriptum, and angiokeratoma of Mibelli). 9141/0 | morphology || Angiokeratoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C2915 Carcinoid Tumor A slow growing neuroendocrine tumor, composed of uniform, round, or polygonal cells having monotonous, centrally located nuclei and small nucleoli, infrequent mitoses, and no necrosis. The tumor may show a variety of patterns, such as solid, trabecular, and acinar. Electron microscopy shows small secretory granules. Immunohistochemical studies reveal NSE, as well as chromogranin immunoreactivity. Malignant histology (cellular pleomorphism, hyperchromatic nuclei, prominent nucleoli, necrosis, and mitoses) can occasionally be seen. Such cases may have an aggressive clinical course. Gastrointestinal tract and lung are common sites of involvement. 8240/3 | morphology || 8241/3 | morphology || Carcinoid tumor, NOS | primary_diagnosis || Carcinoid, NOS | primary_diagnosis || Enterochromaffin cell carcinoid | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C3254 Angiomyxoma A benign soft tissue neoplasm characterized by the presence of neoplastic spindle and stellate cells, and vascular proliferation in a myxoid stroma. 8841/1 | morphology || Angiomyxoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C4173 Papillary Eccrine Adenoma A benign neoplasm arising from the sweat glands. It is characterized by the presence of eccrine ducts in the dermis containing intraluminal papillary projections. 8408/0 | morphology || Eccrine papillary adenoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C4225 Cutaneous Nodular Melanoma An aggressive form of melanoma, frequently metastasizing to the lymph nodes. It presents as a papular or nodular raised skin lesion. It comprises approximately 10-15% of melanomas. Morphologically, it often displays an epithelioid appearance. 8721/3 | morphology || Nodular melanoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C43333 Spindle-Cell Predominant Trichodiscoma A benign tumor usually arising in the face, trunk or thighs. 8391/0 | morphology || Trichodiscoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C43342 Apocrine Hidrocystoma A slow-growing, usually solitary, dome-shaped benign sweat gland adenoma, most frequently located on the eyelid. It is characterized by a cystic proliferation of apocrine glands. Surgical excision is curative. 8401/0 | morphology || Apocrine cystadenoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C66903 Skin Metatypical Carcinoma A skin carcinoma displaying cytological characteristics intermediate to nodular basal cell carcinoma and squamous cell carcinoma. 8095/3 | morphology || Metatypical carcinoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C9152 Low-CSD Melanoma A type of melanoma that typically occurs in light-skinned individuals ranging in age from young adults to the elderly. Risk factors include extensive sun exposure during childhood, a family history of melanoma, and the presence of dysplastic nevi. 8743/3 | morphology || Superficial spreading melanoma | primary_diagnosis C176985 || C177621 morphology || primary_diagnosis D C177537 GDC Value Terminology C99459 Recombinant Oncolytic Poliovirus PVS-RIPO A recombinant, live attenuated, nonpathogenic oncolytic virus containing the oral poliovirus Sabin type 1 in which the internal ribosomal entry site (IRES) is replaced with the IRES from human rhinovirus type 2 (HRV2), with potential antineoplastic activity. Upon intratumoral administration of recombinant oncolytic poliovirus PVS-RIPO, the poliovirus is selectively taken up by and replicates in tumor cells expressing CD155 (poliovirus receptor, PVR or NECL5) eventually causing tumor cell lysis. CD155, an oncofetal cell adhesion molecule and tumor antigen, is ectopically expressed in certain cancers, such as glioblastoma multiforme (GMB), and plays an important role in tumor cell migration, invasion, and metastasis. Due to the heterologous HRV2 IRES in this recombinant virus, PVS-RIPO only propagates in susceptible, nonneuronal cells (e.g., GBM). Recombinant Oncolytic Poliovirus PVS-RIPO | therapeutic_agents C1909 therapeutic_agents